24 November 2015
EMA/HMPC/436680/2015
Committee on Herbal Medicinal Products (HMPC)

Assessment report on **Althaea officinalis** L., radix
Draft - revision

Based on Article 16d(1), Article 16f and Article 16h of Directive 2001/83/EC as amended (traditional use)

<table>
<thead>
<tr>
<th>Herbal substance(s) (binomial scientific name of the plant, including plant part)</th>
<th><strong>Althaea officinalis</strong> L., radix</th>
</tr>
</thead>
<tbody>
<tr>
<td>Herbal preparation(s)</td>
<td>Comminuted herbal substance Liquid extract (DER 1:19.5–23.5), extraction solvent water Macerate for preparation of syrup Dry extract (DER 3–9:1), extraction solvent water Liquid extract (DER 1:1), extraction solvent ethanol 25% (V/V)</td>
</tr>
<tr>
<td>Pharmaceutical form(s)</td>
<td>Comminuted herbal substance as herbal tea for oral use. Herbal preparations in liquid or solid dosage forms for oral or oromucosal use.</td>
</tr>
<tr>
<td>Rapporteur(s)</td>
<td>M. Heroutová</td>
</tr>
<tr>
<td>Peer-reviewer</td>
<td>G. Laekeman</td>
</tr>
</tbody>
</table>

Note: This draft assessment report is published to support the public consultation of the draft European Union herbal monograph on **Althaea officinalis** L., radix. It is a working document, not yet edited, and shall be further developed after the release for consultation of the monograph. Interested parties are welcome to submit comments to the HMPC secretariat, which will be taken into consideration but no "overview of comments received during the public consultation" will be prepared on comments that will be received on this assessment report. The publication of this draft assessment report has been agreed to facilitate the understanding by Interested Parties of the assessment that has been carried out so far and led to the preparation of the draft monograph.
Table of contents

Table of contents .................................................................................................................. 2

1. Introduction .......................................................................................................................... 4
  1.1. Description of the herbal substance(s), herbal preparation(s) or combinations thereof .. 4
  1.2. Search and assessment methodology ............................................................................. 7

2. Data on medicinal use .......................................................................................................... 7
  2.1. Information about products on the market ........................................................................ 7
  2.1.1. Information about products on the market in the EU/EEA Member States ................. 7
  2.1.2. Information on products on the market outside the EU/EEA ...................................... 11
  2.2. Information on documented medicinal use and historical data from literature ............ 12
  2.3. Overall conclusions on medicinal use ............................................................................. 23

3. Non-Clinical Data .................................................................................................................... 28
  3.1. Overview of available pharmacological data regarding the herbal substance(s), herbal preparation(s) and relevant constituents thereof ......................................................... 28
    3.1.1. Primary pharmacodynamics ....................................................................................... 28
    3.1.2. Secondary pharmacodynamics .................................................................................. 33
    3.1.3. Safety pharmacology ............................................................................................... 34
    3.1.4. Pharmacodynamic interactions ............................................................................... 34
    3.1.5. Conclusions ............................................................................................................. 34
  3.2. Overview of available pharmacokinetic data regarding the herbal substance(s), herbal preparation(s) and relevant constituents thereof ......................................................... 34
  3.3. Overview of available toxicological data regarding the herbal substance(s)/herbal preparation(s) and constituents thereof ................................................................. 35
    3.3.1. Single dose toxicity .................................................................................................. 35
    3.3.2. Repeat dose toxicity ............................................................................................... 35
    3.3.3. Genotoxicity ........................................................................................................... 35
    3.3.4. Carcinogenicity ...................................................................................................... 35
    3.3.5. Reproductive and developmental toxicity ............................................................... 35
    3.3.6. Local tolerance ...................................................................................................... 35
    3.3.7. Other special studies ............................................................................................... 35
    3.3.8. Conclusions ........................................................................................................... 35
  3.4. Overall conclusions on non-clinical data ...................................................................... 36

4. Clinical Data .......................................................................................................................... 36
  4.1. Clinical pharmacology .................................................................................................... 36
    4.1.1. Overview of pharmacodynamic data regarding the herbal substance(s)/preparation(s) including data on relevant constituents ................................................................. 36
    4.1.2. Overview of pharmacokinetic data regarding the herbal substance(s)/preparation(s) including data on relevant constituents ................................................................. 36
  4.2. Clinical efficacy .............................................................................................................. 36
    4.2.1. Dose response studies ............................................................................................. 36
    4.2.2. Clinical studies (case studies and clinical trials) ....................................................... 36
  4.3. Clinical studies in special populations (e.g. elderly and children) ............................. 40
  4.4. Overall conclusions on clinical pharmacology and efficacy ........................................... 40

5. Clinical Safety/Pharmacovigilance ...................................................................................... 41
  5.1. Overview of toxicological/safety data from clinical trials in humans ......................... 41
5.2. Patient exposure ........................................................................................................43
5.3. Adverse events, serious adverse events and deaths..............................................43
5.4. Laboratory findings ....................................................................................................43
5.5. Safety in special populations and situations ..........................................................43
5.5.1. Use in children and adolescents ........................................................................43
5.5.2. Contraindications ..................................................................................................43
5.5.3. Special Warnings and precautions for use ..........................................................43
5.5.4. Drug interactions and other forms of interaction ................................................44
5.5.5. Fertility, pregnancy and lactation ........................................................................44
5.5.6. Overdose ...............................................................................................................44
5.5.7. Effects on ability to drive or operate machinery or impairment of mental ability .....45
5.5.8. Safety in other special situations .........................................................................45
5.6. Overall conclusions on clinical safety .......................................................................45

6. Overall conclusions (benefit-risk assessment) ..........................................................45

Annex .............................................................................................................................46
1. Introduction

1.1. Description of the herbal substance(s), herbal preparation(s) or combinations thereof

- Herbal substance(s)

In accordance with the European Pharmacopoeia (8th ed., 01/2012:1126) marshmallow root (Althaeae radix) consists of peeled or unpeeled, whole or cut, dried root of *Althaea officinalis* L. It has a swelling index of minimum 10, determined on the powdered herbal substance.

The unpeeled, non-fragmented drug consists of cylindrical, slightly twisted roots, up to 2 cm thick, with deep longitudinal furrows. The outer surface is greyish-brown and bears numerous rootlet scars. The fracture is fibrous externally, rugged and granular internally. The section shows a more or less thick, whitish bark with brownish periderm, separated by the well-marked, brownish cambium from a white xylem. The stratified structure of the bark and the radiate structure of xylem become more distinct when moistened.

The peeled drug has a greyish-white, finely fibrous outer surface. Cork and external cortical parenchyma are absent. (European Pharmacopoeia 8th ed., 01/2012:1126)

The roots are collected in the autumn from plants not less than two years old (British Pharmaceutical Codex 1949; Hänel et al., 1993; Bradley, 1992).

- Herbal preparation(s)

Comminuted herbal substance for macerate preparation

Liquid extract (DER 1:19.5-23.5), extraction solvent water

Dry extract (DER 3-9:1), extraction solvent water

Macerate for preparation of syrup

Liquid extract (DER 1:1), extraction solvent ethanol 25% (V/V)

Rapporteur’s comment:

The macerate is prepared in accordance with the pharmacopoeial monographs for Sirupus althaeae in Österreichisches Arzneibuch 1981, Československý lékopis 1954, Farmakopea Polska 1970 and 2002 or with the monograph Eibischsirup in Deutscher Arzneimittel-Codex 1979.

Differences in procedures for the preparation of Marshmallow syrup in the pharmacopoeias/handbooks of the EU member states are summarised below:

Český/Československý lékopis, 1954, 2005

Althaeae sirupus is prepared from cold macerate (25 g Althaeae radix in the mixture of 10 g of ethanol 96 % and 400 g of purified water, time of maceration 2 hours); to 360 g of the cold macerate 640 g of sucrose is added. The product is stabilised with methylparaben.

Österreichisches Arzneibuch, 1981, 2013

Althaeae sirupus is prepared by maceration of 5 parts of root with 110 parts of purified water for 2 hours. After filtering 100 parts of the filtrate are boiled with 160 parts of sucrose. Finally, the ethanolic solution of the preservatives is added.
Deutscher Arzneimittel Codex, 1979, 2004
Althaea sirupus is prepared by maceration of 20 parts of root with 450 parts of purified water under stirring for 2 hours. The macerate is weighed; to 1 part of macerate 1.78 parts of sucrose are added and dissolved at 50°C under stirring. Short boiling follows. Finally, the ethanolic solution of the preservatives is added.

Farmakopea Polska, 2002
Althaea sirupus is prepared by maceration of 5 parts of root with 1 part of ethanol (760 g/l) and 40 parts of purified water for 3 hours without stirring. In macerate obtained 64 parts of sucrose and 0.1 part of benzoic acid are solved. Short boiling follows.

Farmakopea Polska, 1954, 1970
Althaea sirupus is prepared by maceration of 2 parts of root with 1 part of ethanol (95°) and 40 parts of purified water for 3 hours without stirring. In macerate obtained 64 parts of sucrose and 0.1 part of benzoic acid are solved. Short boiling follows.

Table 1: Differences in Marshmallow syrup preparation described in MS pharmacopoeias/handbooks

<table>
<thead>
<tr>
<th>Source</th>
<th>Macerate preparation Althaea radix/water</th>
<th>Sucrose added amount</th>
<th>Other components</th>
<th>Density/ Relative density</th>
<th>Amount of drug substance corresponding to 10 ml of syrup*</th>
</tr>
</thead>
<tbody>
<tr>
<td>BPC 1949</td>
<td>40 g /560 ml maceration for 12 hours</td>
<td>900 g</td>
<td>Chloroform 2.5 ml</td>
<td>1.26-1.30 g/ml</td>
<td>ca 0.35 g</td>
</tr>
<tr>
<td>ÖAB 1981/2013</td>
<td>5 p/110 p, maceration for 2 hours under frequent stirring</td>
<td>160 p/100 p of macerate</td>
<td>Preservatives 0.18 p MPB + 0.09 p PPB /1.5 p ethanol</td>
<td>1.29-1.32</td>
<td>ca 0.27 g</td>
</tr>
<tr>
<td>DAC 1979/2004</td>
<td>20 p/450 p maceration for 2 hours under frequent stirring</td>
<td>1.78 x macerate amount</td>
<td>Preservatives 0.25 p PPB + 0.75 p MPB/ethanol ad 10 p</td>
<td>1.295-1.326</td>
<td>ca 0.21 g</td>
</tr>
<tr>
<td>ČL/ČSL 2005/1954</td>
<td>25g/mixture of 400 g water + 10 g ethanol, maceration for 2 hours</td>
<td>640 g /360 g of macerate</td>
<td>Preservative MPB 1.5 g/10 g ethanol</td>
<td>1.30-1.32 g/cm³</td>
<td>ca 0.29 g</td>
</tr>
<tr>
<td>Farmakopea Polska VI. ed. 2002</td>
<td>5 p/ethanol 760 g/l - 1 p/40 p water maceration for 3 hours</td>
<td>64 p/100 p of the product</td>
<td>Preservative benzoic acid 0.1 p/100 p of the product</td>
<td>1.300-1.320 g/cm³</td>
<td>ca 0.58 g</td>
</tr>
<tr>
<td>Farmakopea Polska III. ed., 1954</td>
<td>2 p/ethanol 95° 1p/40 p water for maceration for 3 hours</td>
<td>64 p/100 p of the product</td>
<td>Preservative benzoic acid 0.1 p/100 p of the product</td>
<td>1.300-1.320 g/cm³</td>
<td>ca 0.23 g</td>
</tr>
</tbody>
</table>

Abbreviations:
p – parts; MPB – methylparaben; PPB – propylparaben; BPC – British Pharmaceutical Codex ; ÖAB – Österreichisches Arzneibuch ; DAC – Deutscher Arzneimittel Codex ; ČL – Český lékopis (Czech Pharmacopoeia; ČSL - Československý lékopis (Czechoslovak Pharmacopoeia)
* water absorbed by the herbal drug was not taken in consideration

Althaea syrup as defined in the British Pharmaceutical Codex 1949 is considered obsolete due to chloroform content and its potentially carcinogenic effect. Chloroform content in this product is ca 2500 ppm.
Cold macerates in syrups correspond to 0.21 – 0.58 g of marshmallow root in 10 ml of the product.

Traditional use registration based on the pharmacopoeia monograph published in Farmakopea Polska VI. Edition (2002) was already granted in Poland.

**Principal constituents of the herbal substance**

**Mucilage polysaccharides**

5-11.6 % mucilage (depending on vegetative period) – consisting of the mixture of colloiddally soluble polysaccharides (Franz, 1966), particularly of acid arabinogalactans, galacturonic rhamnans, arabans and glucans acidic heteropolysaccharide (with a MW ca 30 000) containing D-galactose, L-rhamnose, D-glucuronic acid and D-galacturonic acid in the molar ratios 1.2:1.0:1.0:1.0 (Capek et al., 1987) or in molar ratios 2:3:3:3 (Tomoda et al., 1977), L-arabinans (Capek et al., 1983); D-glucans (Capek et al., 1984). Dominant neutral mucilage component is (1→6)-α-D-glucan (Nosálova et al., 1992, 1993).

By partial acid hydrolysis Althaea mucilage O (representative mucous polysaccharide isolated from the roots of *Althaea officinalis* L.) the following oligosaccharides were obtained: O-α-(D-galactopyranosyluronic acid)-(1→2)-L-rhamnopyranose, O-β-(D-glucopyranosyluronic acid)-(1→3)-O-α-(D-galactopyranosyluronic acid)-(1→2)-L-rhamnopyranose and hexasaccharide, nonasaccharide, dodecasaccharide composed of a repeating unit having the structure of the trisaccharide through position 4 of the D-galacturonic acid residue (Tomoda et al., 1980).

Partial acid hydrolysis of heteropolysaccharide isolated from the mucilage of the marshmallow indicated that the polymer backbone is composed of (1→4)-linked D-galactopyranuronic acid and (1→2)-linked L-rhamnopyranose units in the ratio of 1:1. Each D-galacturonic unit carries a single β-D-glucopyranuronic residue linked to C-3, and each L-rhamnopyranose unit carries D-galactopyranose residues, mainly as non-reducing terminals linked to C-4 (Capek et al., 1987). In addition to reducing oligosaccharides, two other non-reducing oligosaccharides: α-D-galactopyranuronic acid, β-L-rhamnopyranose 1,2´:2,1´-dianhydride and 3-O-(β-D-glucopyranosyluronic acid)-α-D-galactopyranuronic acid β-L-rhamnopyranose 1,2´:2,1´-dianhydride have been identified (Capek et al., 1988).

In hydrolysates of mucilages isolated from roots, leaves and flowers of *Althaea officinalis* L. and *Malva silvestris* L. ssp. *mauritiana* (L.) Thell., D-galactose, D-glucose, D-mannose, L-rhamnose, D-xylose, L-arabinose, D-galacturonic acid, and D-glucuronic acid were identified (Rosik et al., 1984).

**Pectins**

11 % (Blumenthal et al., 2000)

**Starch**

25-35 % (Blumenthal et al., 2000)

**Mono-, Di-saccharides**

saccharose 10 % (Gudej, 1991); crude mucilages contained 5 % glucose in spring and 20 % glucose in winter (Franz, 1966)

**Flavonoids**

0,14 – 0.28 % (Gudej, 1990)

Hypolaetin-8-glucoside, isoscetullarein-4´-methyl ether 8-O-β-D-glucoside-2´-SO₃K (Gudej, 1991), kaempferol, quercetin, isouqueretin, astragalin (Ionkova, 1992), naringenin (Ninov et al., 1992), hypolaetin-8-O-β-D-glucuronoyranosyl-1″,4″-O-D-glucopyanosid, hypolaetin-4´-methylether-8-O-β-D-glucopyanosid-2″-O-sulfat, hypolaetin-8-O-β-D-glucopyanosid-2″-O-sulfat, isoscetullarein-4´-methylether-8-O-β-D-glucuronoyranosid-3″-O-sulfat, hypolaetin-4´-methylether-8-O-β-D-glucuronoyranosid-3″-O-sulfat,
hypolaetin-4′-methylether-8-O-β-D-glucuronopyranosid-3″-O-sulfat, hypolaetin-8-O-β-D-glucuronopyranosid-3″-O-sulfat (Theograndin II) (Böker 2013)

**Phenolic acids**
caffeic, p-coumaric, ferulic, p-hydroxybenzoic, salicylic, syringic, p-hydroxyphenylacetic, vanillic acid (Gudej, 1991)

**Coumarins**
scopoletin (Gudej, 1991; Ionkova, 1992) scopoletin-O-β-D-glucopyranosyl-L-rhamnopyranosid (Böker 2013)

**Other compounds**
phytosterols (Wichtl, 1994), calcium oxalate (Blumenthal et al., 2000), fat, tannins (Bradley, 1992), amino acids (Rosík et al., 1984; Böker et al., 2012), 2 % asparagine (Bradley, 1992), glycine betain (Böker et al., 2012)

- Combinations of herbal substance(s) and/or herbal preparation(s) including a description of vitamin(s) and/or mineral(s) as ingredients of traditional combination herbal medicinal products assessed, where applicable.

Not applicable.

### 1.2. Search and assessment methodology

Databases and other sources used to research available pharmaceutical, non-clinical and clinical data on *Althaea officinalis* L, root. or its relevant constituents.


Literature was provided by Kooperation Phytopharmaka in response to the call for scientific data in December 2014.

Libraries: EMA library, library of the State Institute of Drug Control, Prague.

Textbooks, pharmacopoeias and monographs.

A literature search was performed in April 2015.

### 2. Data on medicinal use

#### 2.1. Information about products on the market

#### 2.1.1. Information about products on the market in the EU/EEA Member States

**Information on medicinal products marketed in the EU/EEA**

According to the information provided by the National Competent Authorities in the overview of the marketed products, the following herbal substances/preparations have been marketed in the EU/EEA:
Table 2: Overview of data obtained from marketed medicinal products

<table>
<thead>
<tr>
<th>Active substance</th>
<th>Indication</th>
<th>Pharmaceutical form</th>
<th>Regulatory Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Comminuted herbal substance for macerate or infusion preparation</td>
<td>Sore throat and upper respiratory complaints</td>
<td>Herbal tea: 10 g of the comminuted herbal substance in 200 ml of water as a macerate Single dose 60 ml 2 – 3 times daily</td>
<td>Poland, more than 30 years</td>
</tr>
<tr>
<td></td>
<td>Irritation of the oral and pharyngeal mucosa and associated dry cough</td>
<td>Herbal tea prepared from up to 6g/daily (6g divided in two or three portions)</td>
<td>Spain, before 1973</td>
</tr>
<tr>
<td></td>
<td>An adjuvant in treatment of bronchitis; traditionally used in occasional mild cough; traditionally used to alleviate abdominal aches of digestive origin</td>
<td>1 cup of infusion prepared from 1 teaspoon (approximately 2 g) and 200 ml of boiling water 2 to 3 times daily.</td>
<td>Romania, since 2001</td>
</tr>
<tr>
<td>Liquid extract of Althaeae radix (1:19,5-23,5), extraction solvent: water</td>
<td>Irritations of the mucosa in the oropharynx and therewith associated hacking dry cough.</td>
<td>Syrup, 100g (=76,44ml) syrup contains 35,610g liquid extract Adolescents and adults &gt; 12: single dose 10 ml syrup corresponds to 4.6 g liquid extract, 3-6 times daily Children between 6 and 12 years of age: single dose 5 ml syrup corresponds to 2.3 g liquid extract, 5 times daily, Children between 3 and 5 years of age: single dose 4 ml corresponds to 1.9 g liquid extract, 4 times daily, Children between 1 and 2 years of age: single dose 3ml corresponds to 1.4 g liquid extract, 4 times daily</td>
<td>Germany, WEU, at least since 1976 Netherlands, TU 2013</td>
</tr>
</tbody>
</table>

Assessment report on Althaea officinalis L., radix
EMA/HMPC/436680/2015
<table>
<thead>
<tr>
<th><strong>Active substance</strong></th>
<th><strong>Indication</strong></th>
<th><strong>Pharmaceutical form</strong></th>
<th><strong>Regulatory Status</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Dry extract of Althaeae radix (3-9:1), extraction solvent: water</td>
<td>Traditional herbal medicinal product for use as a demulcent preparation for the symptomatic treatment of oral or pharyngeal irritation and associated dry cough.</td>
<td>Lozenge, 160mg Adolescents and adults &gt;12: single dose 1 lozenge, several times daily if needed up to a maximum daily dose of 10 lozenges Children between 6 and 12 years of age: single dose 1 lozenge, 3 times daily</td>
<td>Germany, TU 2013</td>
</tr>
<tr>
<td>Syrup</td>
<td>A demulcent for symptomatic treatment of dry irritable cough</td>
<td>Syrup prepared from the macerate (34.9 g) of 2 g Althaeae radix The dosage is 2-8 ml. No information on frequency of use is available.</td>
<td>Lithuania, more than 100 years</td>
</tr>
<tr>
<td>Traditional herbal medicinal product used for relieve of symptoms of upper respiratory tract irritations with accompanying cough.</td>
<td>100g of product contains macerate of 5 parts of <em>Althaea officinalis</em>, radix, with 40 parts of water + 1 part of ethanol 96% (v/v). Dosage: children 6-12 years of age 5 ml 3 times a day, adolescents and adults 15 ml 3 times a day</td>
<td></td>
<td>Poland, traditional registration, 2014</td>
</tr>
<tr>
<td>Traditional medicinal product used as a means of soothing the symptoms of irritation of oral and throat mucosa and accompanying cough.</td>
<td>100g of syrup contains macerate of 2 parts of <em>Althaea officinalis</em>, radix, with 40 parts of water + 1 part of ethanol 96% Dosage: children 3-6 years of age 5 ml up to 4 times daily, children 6-12 years of age 5 ml up to 5 times daily, adolescents and adults 10ml 3 – 5 daily. No restriction of therapy duration.</td>
<td></td>
<td>National authorisation, 05.07.1996, based on Polish Pharmacopoeia III 1954. TU, 2015, Poland</td>
</tr>
<tr>
<td>Syrup</td>
<td>Traditional medicinal product possessing coating abilities. It is used for relieve of symptoms of irritation of oral cavity and</td>
<td>Syrup. 100g of product contains macerate of 5 parts of <em>Althaea officinalis</em>, radix, with 40 parts of water + 1 part of ethanol 96%</td>
<td>Poland, national authorisation, since 28.5.2011</td>
</tr>
<tr>
<td>Active substance</td>
<td>Indication</td>
<td>Pharmaceutical form</td>
<td>Regulatory Status</td>
</tr>
<tr>
<td>------------------------</td>
<td>----------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td></td>
<td>throat mucosa and accompanying dry cough</td>
<td>Dosage: children 3-6 years of age 2,5-5ml 3 x daily, children 6-12 years of age 5-10 ml 3 x daily, adolescents and adults 10-15 ml 3 x daily. Duration not restricted</td>
<td>Poland, National authorisation, since 10.02.2000</td>
</tr>
<tr>
<td>Traditional medicinal product possessing coating abilities. It is used for relieve of symptoms of irritation of oral cavity and throat mucosa and accompanying cough</td>
<td>Syrup. 100g of product contains macerate of 5 parts of <em>Althaea officinalis</em>, radix, with 40 parts of water + 1 part of ethanol 96% (v/v) Dosage: children 3-6 years of age 2,5-5ml (1/2-1 teaspoon) 3 – 4 x daily, children 6-12 of age 5 ml (1 teaspoon) 3–4 x daily adolescents and adults 15 ml 3 – 4 x daily. Duration of use not limited.</td>
<td>Poland, National authorisation, since 2006, based on Polish Pharmacopoeia VI 2002.</td>
<td></td>
</tr>
<tr>
<td>Syrup</td>
<td>Dry cough, irritation of oral cavity and throat mucosa</td>
<td>Syrup. 100g of product contains macerate of 5 parts of <em>Althaea officinalis</em>, radix, with 40 parts of water + 1 part of ethanol 96% (v/v) Dosage: children 6-12 years of age 2,5 ml (1/2 teaspoon) 2 x daily, adolescents and adults 2,5 – 10ml 3 x daily. Duration of use not limited.</td>
<td>Poland, National authorisation since 2006, based on Polish Pharmacopoeia VI 2002.</td>
</tr>
<tr>
<td>Althaea polysaccharides</td>
<td>An expectorant</td>
<td>1 tablet containing 50 mg of Althaea polysaccharides twice daily</td>
<td>Estonia, food supplement since 2004</td>
</tr>
</tbody>
</table>

This overview is not exhaustive. It is provided for information only and reflects the situation at the time when it was established.
Information on relevant combination medicinal products marketed in the EU/EEA

The following relevant combination product is registered in the EU/EEA:

An oral solution containing 0.83 g of liquid extract (DER1:12-14) of the root of Althea officinalis L., extraction solvent water and 0.12 g of dry extract (DER:7-13:1) of Thymus vulgaris L. or Thymus zygis L. (leaves and flowers) extraction solvent water in 15 ml is registered in several member states (Croatia, Spain, Ireland, Austria, Bulgaria, Italy, Hungary, Portugal, Sweden, Slovenia and UK) and in Norway.

Indication: Traditional herbal medicinal product used in productive cough associated with cold, and to relieve pharyngeal irritation and associated dry cough.

Posology: Adults and adolescents: 15 ml every 4 hours (4 times per day). If needed the maximum daily dose is 90 ml (6 doses per day).

Children 6-12 years of age: 7.5 ml every 3-4 hours (4 times per day). If needed the maximum daily dose is 45 ml (6 doses per day).

Additional relevant combination products marketed in the EU/EEA are the following:

**Croatia**

Syrup containing 0.77 g liquid extract from Thymus vulgaris L. or Thymus zygis L., herba (1:2–2.5); extraction solvent: ammonia solution 10 % m/m: glycerol 85 % m/m: ethanol 90 % V/V: water (1:20:70:109) and 0.66 g liquid extract from Althaeae officinalis L., radix (1:20), extraction solvent: water in 5 ml

Indication: irritation of the throat; productive cough associated with cold

Posology: Adults and adolescents older than 12 years: 10 ml every 3 hours to 6 times daily

**Latvia**

Syrup containing 0.12 g Thymi herbæ extractum siccum (7-13:1, extraction solvent: water) and 3.33 g Althaeae radicis sirupus in 15 ml

Indication: Herbal cough suppressant with an expectorant, antispasmodic and anti-irritant effect.

Posology: adults and adolescents (from 12 years) 15 ml each 3-4 hours (4-6 times per day, max daily dose - 90 ml), children (3-12 years) 7.5 ml each 3-4 hours (4-6 times per day, max daily dose - 45 ml).

On the market since 2012 (TU).

Syrup containing 0.77 g Thymi herbæ extractum fluidum ((1:2-2.5), extraction solvent: ammonia solution 10%(m/m):glycerol 85%(m/m) :ethanol 90% (v/v):water (1:20:70:109)) and 1.710 g Althaeae radicis sirupus in 5 ml contains.

Indication: For relief of throat irritation and cough, expectorant.

Posology: adults and adolescents (from 12 years): 10 ml each 3 hours up to 6 times per day (4-6 times per day, max daily dose - 60 ml), children (4-12 years) 5 ml each 3 hours up to 6 times per day (max daily dose - 30 ml)

On the market since 2012 (TU).

Information on other products marketed in the EU/EEA (where relevant)

Not applicable.

2.1.2. Information on products on the market outside the EU/EEA

Not applicable.
2.2. Information on documented medicinal use and historical data from literature

Marshmallow has been used in traditional European medicine since ancient times. Althaea is often mentioned by ancient authors; however, it is not clear whether information is related really to *Althaea officinalis* as Theophrast describes his Althaea with yellow and Dioskurides with rose rot flowers. Hippocrates recommends decoction from the root as a wound remedy while Dioskurides in anuria, diarrhoea, lithiasis, internal injuries, nerve pain, bee sting, tooth-ache etc. In the Middle Ages Althaea was prescribed by Paracelsus as abscess emollient and cleanser, by Lonicerus and Matthiolus as an expectorant and diuretic, in internal injuries, externally as ulcers emollient, for burns treatment etc. (Madaus, 1938).


The following traditional uses and posologies have been recorded for marshmallow root

*Lehrbuch der Biologischen Heilmittel* (Madaus, 1938)

**Indications:** supportive treatment of respiratory catarrhs associated with irritation of respiratory organs, cough, and hoarseness; inflammations of urogenital and gastrointestinal tracts (cystitis, nephrolithiasis, enteritis, diarrhoea, gastric and duodenal ulcers), topically – as a gurgle in mouth inflammations; eye and skin inflammations; burns; furunculosis and carbunculosis

**Dosage:** daily dose – macerate prepared from 4 spoons of Marshmallow root (17.2 g); 1 spoon of the “teep” preparation (50% of marshmallow root) 3 times daily

**Duration of use:** no information.

*British Herbal Pharmacopoeia 1983*

Demulcent, diuretic, emollient, vulnerary

**Indications:** gastritis, gastric and peptic ulceration, enteritis; inflammation of the mouth and pharynx, respiratory catarrh with irritating cough; cystitis; locally – varicose and thrombotic ulcers

**Dosage:** three times daily dried root 2-5 g or by cold extraction; liquid extract 1:1 in ethanol 25% 2-5 ml three times daily, syrup (BPC 1949) 2-10 ml 3 times daily; ointment 5% powdered Althaea root in usual ointment base

**Duration of use:** no information.

*The Complete German Commission E Monographs* (Blumenthal et al., 1998)

**Indications:** Irritation of the oral and pharyngeal mucosa and associated dry cough. Mild inflammation of the gastric mucosa.

**Daily oral dose:** 6 g of root or equivalent amount of preparations. “Marshmallow syrup”: single dose 10 g.

**Duration of use:** no information.
The Expanded Commission E Monographs (Blumenthal et al., 2000)

**Dosage:** unless otherwise prescribed: 6 g per day of cut or ground root. Cold maceration: 2-5 g to 150 ml cold water for 30 minutes stirring frequently; strain and warm before drinking, up to three times a day. Dried root: 2-5 g, up to three times a day. Fluid extract 1:1 (g/ml): 2-5 ml, up to 3 times a day. Tincture 1:5 (g/ml), up to three times a day. Native dry extract 3.5-5.0:1 (w/w): 0.4-0.6 g, up to three times a day. Sirupus Althaeae: single dose: 10 ml, to be used only in treating throat irritation.

**Duration of use:** no information.

WHO Monographs on Selected Medicinal Plants (Volume 2, 2002).

**Indications:** As a demulcent for symptomatic treatment of dry irritable coughs and irritations of oral and pharyngeal mucosa and as an emollient for wounds and dry skin.

**Dosage:** for dry cough, oral and pharyngeal irritation – 0.5 – 3.0 g of the crude drug as a macerate up to daily dose of 15 g of crude drug, syrup 2 – 8 ml; for gastric irritation – 3 – 5 g of crude drug as a macerate up to three times daily

**Duration of use:** no information.

ESCAP Monographs (2003)

**Indications:** Dry cough; irritation of the oral, pharyngeal or gastric mucosa.

**Adult single dose:** For dry cough and oral or pharyngeal irritation, 0.5-3 g of the drug as an aqueous cold macerate, or 2-8 ml of syrup, repeated if required up to daily dose equivalent to 15 g of the drug. For gastrointestinal irritation, 3-5 g as an aqueous cold macerate up to 3 times daily.

**Duration of use:** no restriction.

British Herbal Compendium (Bradley, 1992)

**Indications:**
Internally: for gastroenteritis, peptic or duodenal ulceration, common and ulcerative colitis and enteritis. Topically: as mouthwash or gargle for inflammation of the pharynx and as a poultice or ointment/cream in furunculosis, eczema and dermatitis.

**Dosage:** 3 times daily dried root, 2-5 g or as a cold infusion; tincture (1:5), 25 % ethanol, 5-15 ml; syrup (BPC 1949), 2-10 ml, 5-10 % preparations in an ointment or cream base

**Duration of use:** no restriction.

The British Pharmaceutical Codex (1949)

**Indications:** Althaea is demulcent and emollient and is given by mouth in the treatment of bronchitis. It may be given in the form of syrup. Althaea has been applied to inflamed tissues as fomentation (1 part of powdered root to 5 parts of water).

**Dosage:** no information.

**Duration of use:** no information.

Althaeae sirupus: 40 g of Althaeae radix are macerated with 560 ml of water for 12 hours and filtered. In the filtrate 900 g of sucrose is dissolved, heated to boiling and cooled. Any water lost by evaporating is replaced. At the end 2.5 ml of chloroform is added.

**Dosage:** 2-8 ml.

Herbal Medicines. A guide for healthcare professionals (Barnes et al., 2002, Newal et al., 1996)

**Indications:** Traditionally used internally for the treatment of respiratory catarrh and cough, peptic ulceration, inflammation of the mouth and pharynx, enteritis, cystitis, urethritis, and urinary calculus and topically: for abscesses, boils and varicose and thrombotic ulcers.
**Dosage:** Dried root 2-5 g or by cold extraction three times daily; 6 g; Root liquid extract (1:1 in 25 % alcohol) 2-5 ml three times daily; Syrup of Althaea (BPC 1949) 2-10 ml three times daily.

**Duration of use:** no information.

**Martindale Extra Pharmacopoeia (1977)**

**Indications:** Althaea is a demulcent and emollient, for irritation and inflammation of the mucous membranes of the mouth and pharynx. The boiled and bruised root has been used as a poultice.

**Dosage:** syrup (BPC 1949) 2-8 ml.

**Duration of use:** no information.

**VIth Hungarian Pharmacopoeia Volume III and IV (1970)**

**Dosage:** dried root, average single dose: 0.50-1.00; average daily dose: 1.5-5.0 g

**Dosage for children**

<table>
<thead>
<tr>
<th>Children age</th>
<th>Single dose (g)</th>
<th>Daily dose (g)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 year</td>
<td>0.12</td>
<td>0.6</td>
</tr>
<tr>
<td>3 years</td>
<td>0.20</td>
<td>1.0</td>
</tr>
<tr>
<td>6 years</td>
<td>0.30</td>
<td>1.5</td>
</tr>
<tr>
<td>9 years</td>
<td>0.50</td>
<td>2.5</td>
</tr>
<tr>
<td>12 years</td>
<td>0.60</td>
<td>3.0</td>
</tr>
<tr>
<td>15 years</td>
<td>0.80</td>
<td>4.0</td>
</tr>
</tbody>
</table>

**Český lékopis, 2005**

**Dosage:** Althaeae radix: for the treatment of upper respiratory tract inflammations – single dose 0.5-3.0 g, daily dose 15.0 g and for the treatment of gastrointestinal inflammations – single dose 3.0-5.0 g, daily dose 6.0-15.0 g.

**Československý/Český lékopis, 1954, 2005**

Althaeae sirupus is prepared from cold macerate (25 g Althaeae radix in the mixture of 10 g of ethanol 96 % and 400 g of purified water, time of maceration 2 hours); to 360 g of the cold macerate 640 g of sucrose is added. The product is stabilised with methylparaben. No information on syrup dosage.

**Duration of use:** no information.


**Dosage:** Althaeae radix: Single dose as a macerate 1.5 g for 1 cup.

Althaeae sirupus is prepared by maceration of 5 parts of root with 110 parts of purified water for 2 hours. After filtering 100 parts of the filtrate are boiled with 160 parts of sucrose. Finally, the ethanolic solution of the preservatives is added. No information on syrup dosage.

**Duration of use:** no information.

**Deutscher Arzneimittel Codex, 1979, 2004**

Althaeae sirupus is prepared by maceration of 20 parts of root with 450 parts of purified water under stirring for 2 hours. The macerate is weighed; to 1 part of macerate 1.78 parts of sucrose are added and dissolved at 50°C under stirring. Short boiling follows. Finally, the ethanolic solution of the preservatives is added.
Use: against cough or for addition to cough mixtures.
Dosage: 5-10 ml several times daily.

*Standard Zulassungen für Fertigarzneimittel, 1996*

**Indication:** Irritation of oral and pharyngeal mucosa and associated dry cough, mild irritation of gastric mucosa
**Dosage:** macerate prepared from 2 g/150 ml of water 3 times daily
**Duration of use:** 1 week

*Farmakopea Polska, 2002*

Althaeae sirupus is prepared by maceration of 5 parts of root with 1 part of ethanol (760 g/l) and 40 parts of purified water for 3 hours without stirring. In macerate obtained 64 parts of sucrose and 0.1 part of benzoic acid are solved. Short boiling follows.
**Dosage:** single dose 10-30 g

*Farmakopea Polska, 1954, 1970*

Althaeae sirupus is prepared by maceration of 2 parts of root with 1 part of ethanol (95°) and 40 parts of purified water for 3 hours without stirring. In macerate obtained 64 parts of sucrose and 0.1 part of benzoic acid are solved. Short boiling follows.

*Heilpflanzen Praxis Heute (Bäumler, 2007)*

**Indications:** As a gargle for inflammation of the oral and pharyngeal mucosa; as a demulcent in case of dry cough; for the treatment of mild inflammation of the gastric mucosa and peptic ulcerations; for treatment of small wounds and burns; as a poultice in furunculosis and carbunculosis.
**Dosage:** Daily dose: 6 g of dried root or 10 g of syrup.

**Dosage for children**

<table>
<thead>
<tr>
<th>Children age</th>
<th>Dried root</th>
<th>Syrup</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-1 year</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>1-4 years</td>
<td>1.5-3 g</td>
<td>2-4 g</td>
</tr>
<tr>
<td>4-10 years</td>
<td>3-4 g</td>
<td>4-6 g</td>
</tr>
<tr>
<td>10-16 years</td>
<td>4-6 g</td>
<td>6-10 g</td>
</tr>
</tbody>
</table>

**Duration of use:** no information.

*Kinderdosierungen von Phytopharmaka (Dorsch et al., 2002)*

**Indications:** Irritation of oral and pharyngeal mucosa and associated dry cough, mild irritation of gastric mucosa.

Dosage in adults: 6 g of herbal drug in a form of macerate in 150 ml of cold water several times daily.

**Corresponding dosage in children**

<table>
<thead>
<tr>
<th>0-1 year</th>
<th>1-4 years</th>
<th>4-10 years</th>
<th>10-16 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.5-3 g</td>
<td>3-4 g</td>
<td>4-6 g</td>
<td></td>
</tr>
</tbody>
</table>

Syrup

Dosage in adults: single dose 3-5 g.
**Corresponding dosage in children**

<table>
<thead>
<tr>
<th>Age Group</th>
<th>0-1 year</th>
<th>1-4 years</th>
<th>4-10 years</th>
<th>10-16 years</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2-4 g</td>
<td>4-6 g</td>
<td>6-10 g</td>
<td></td>
</tr>
</tbody>
</table>
Table 3: Overview of historical data

<table>
<thead>
<tr>
<th>Herbal preparation</th>
<th>Documented use / Traditional use</th>
<th>Pharmaceutical form</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Comminuted herbal substance/comminuted herbal substance for macerate preparation</td>
<td>Supportive treatment of respiratory catarrhs associated with irritation of respiratory organs, cough, and hoarseness; inflammations of urogenital and gastrointestinal tracts (cystitis, nephrolithiasis, enteritis, diarrhoea, gastric and duodenal ulcers), topically – as a gurgle in mouth inflammations; eye and skin inflammations; burns; furunculosis and carbunculosis</td>
<td>Daily dose: macerate prepared from 4 spoons of Marshmallow root (17.2 g)</td>
<td>Madaus, 1938</td>
</tr>
<tr>
<td>As a demulcent and emollient for the treatment of bronchitis or as fomentation (1 part of powdered root to 5 parts of water) to be applied to inflamed tissues</td>
<td>No information</td>
<td>No information</td>
<td>British Pharmaceutical Codex 1949</td>
</tr>
<tr>
<td>No information</td>
<td></td>
<td>Adults: average single dose: 0.50-1.00; average daily dose: 1.5-5.0 g</td>
<td>VIth Hungarian Pharmacopoeia 1970</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Children 1 year single dose 0.12 g, daily dose 1.0 g; children 3 years single dose 0.2, daily dose 1.0 g; children 6 years single dose 0.3 g, daily dose 1.5 g; children 9 years single dose 0.5, daily dose 2.5 g; children 12 years single dose 0.6 g, daily dose 3.0 g; children 15 years single dose 0.8 g, daily dose 4.0 g</td>
<td></td>
</tr>
<tr>
<td>A demulcent and emollient, for irritation and inflammation of the mucous membranes of the mouth and pharynx. The boiled and bruised root has been used as a poultice.</td>
<td>No information</td>
<td>No information</td>
<td>Martindale Extra Pharmacopoeia, 1977</td>
</tr>
<tr>
<td>Herbal preparation</td>
<td>Documented use / Traditional use</td>
<td>Pharmaceutical form</td>
<td>Reference</td>
</tr>
<tr>
<td>----------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Gastritis, gastric and peptic ulceration, enteritis; inflammation of the mouth and pharynx, respiratory catarrh with irritating cough; cystitis; locally – varicose and thrombotic ulcers</td>
<td>2-5 g or by cold extraction</td>
<td>Single dose as a macerate 1.5 g for 1 cup.</td>
<td>British Herbal Pharmacopoeia 1983</td>
</tr>
<tr>
<td>No information</td>
<td></td>
<td>Single dose as a macerate 1.5 g for 1 cup.</td>
<td>Österreichisches Arzneibuch 1990</td>
</tr>
<tr>
<td>Internally: for gastroenteritis, peptic or duodenal ulceration, common and ulcerative colitis and enteritis. Topically: as mouthwash or gargle for inflammation of the pharynx and as a poultice or ointment/cream in furunculosis, eczema and dermatitis.</td>
<td>2-5 g or as a cold infusion 3 times daily</td>
<td>Bradley, 1992</td>
<td></td>
</tr>
<tr>
<td>Irritation of oral and pharyngeal mucosa and associated dry cough, mild irritation of gastric mucosa</td>
<td>Macerate prepared from 2 g/150 ml of water 3 times daily Duration of use: 1 week</td>
<td>Standard Zulassungen für Fertigarzneimittel, 1996</td>
<td></td>
</tr>
<tr>
<td>Irritation of the oral and pharyngeal mucosa and associated dry cough. Mild inflammation of the gastric mucosa.</td>
<td>6 g of root or equivalent amount of preparations</td>
<td>Blumenthal et al., 1998</td>
<td></td>
</tr>
<tr>
<td>Reference to the Commission E Monograph, British Herbal Compendium, ESCOP monograph, German Standard Licence</td>
<td>Cold macerate: 2-5 g to 150 ml cold water up to three times a day. Dried root: 2-5 g, up to three times a day.</td>
<td>Blumenthal et al., 2000</td>
<td></td>
</tr>
<tr>
<td>Irritation of oral and pharyngeal mucosa and associated dry cough, mild irritation of gastric</td>
<td>Adults daily dose 6 g; children 1-4 years 1.5 – 3.0 g; children 4 – 10 years 3 – 4 g; children</td>
<td>Dorsch et al., 2002</td>
<td></td>
</tr>
<tr>
<td>Herbal preparation</td>
<td>Documented use / Traditional use</td>
<td>Pharmaceutical form</td>
<td>Reference</td>
</tr>
<tr>
<td>--------------------</td>
<td>----------------------------------</td>
<td>----------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>mucosa</td>
<td>As a demulcent for symptomatic treatment of dry irritable coughs and irritations of oral and pharyngeal mucosa and as an emollient for wounds and dry skin.</td>
<td>For dry cough, oral and pharyngeal irritation – 0.5 – 3.0 g of the crude drug as an macerate up to daily dose of 15 g of crude drug; for gastric irritation – 3 – 5 g of crude drug as a macerate up to three times daily</td>
<td>WHO monographs, 2002</td>
</tr>
<tr>
<td></td>
<td>Internally: for the treatment of respiratory catarrh and cough, peptic ulceration, inflammation of the mouth and pharynx, enteritis, cystitis, urethritis, and urinary calculus topically: for abscesses, boils and varicose and thrombotic ulcers.</td>
<td>2-5 g or by cold extraction three times daily; 6 g</td>
<td>Barnes et al., 2002, Newal et al., 1996</td>
</tr>
<tr>
<td></td>
<td>Dry cough; irritation of the oral, pharyngeal or gastric mucosa.</td>
<td>For dry cough and oral or pharyngeal irritation, 0.5-3 g of the drug as an aqueous cold macerate, repeated if required up to daily dose equivalent to 15 g of the drug. For gastrointestinal irritation, 3-5 g as an aqueous cold macerate up to 3 times daily.</td>
<td>ESCOP Monographs, 2003</td>
</tr>
<tr>
<td></td>
<td>For the treatment of upper respiratory tract and gastrointestinal inflammations</td>
<td>for the treatment of upper respiratory tract inflammations – single dose 0.5-3.0 g, daily dose 15.0 g and for the treatment of gastrointestinal inflammations – single dose 3.0-5.0 g, daily dose 6.0-15.0 g</td>
<td>Český lékopis 2005</td>
</tr>
<tr>
<td></td>
<td>As a gargle for inflammation of the oral and pharyngeal mucosa; as a demulcent in case of dry cough; for the treatment of mild</td>
<td>Adults daily dose 6 g; children 1-4 years 1.5 – 3.0 g; children 4 – 10 years 3 – 4 g; children 10 – 16 years 4 – 6 g</td>
<td>Bäumler, 2007</td>
</tr>
<tr>
<td>Herbal preparation</td>
<td>Documented use / Traditional use</td>
<td>Pharmaceutical form</td>
<td>Reference</td>
</tr>
<tr>
<td>-------------------</td>
<td>--------------------------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>Syrup, BPC 1949</td>
<td>Inflammation of the gastric mucosa and peptic ulcerations; for treatment of small wounds and burns; as a poultice in furunculosis and carbunculosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>As a demulcent and emollient for the treatment of bronchitis</td>
<td>2 – 8 ml</td>
<td>British Pharmaceutical Codex 1949</td>
</tr>
<tr>
<td></td>
<td>A demulcent and emollient, for irritation and inflammation of the mucous membranes of the mouth and pharynx</td>
<td>2 – 8 ml</td>
<td>Martindale Extra Pharmacopoeia, 1977</td>
</tr>
<tr>
<td></td>
<td>Inflammation of the mouth and pharynx, respiratory catarrh with irritating cough</td>
<td>2 – 8 ml 3 times daily</td>
<td>British Herbal Pharmacopoeia, 1983</td>
</tr>
<tr>
<td></td>
<td>Inflammation of the mouth and pharynx</td>
<td>2 – 8 ml 3 times daily</td>
<td>Bradley, 1992</td>
</tr>
<tr>
<td></td>
<td>Internally: for the treatment of respiratory catarrh and cough</td>
<td>2-10 ml three times daily</td>
<td>Barnes et al., 2002; Newal et al., 1996</td>
</tr>
<tr>
<td></td>
<td>As a demulcent for symptomatic treatment of dry irritable coughs and irritations of oral and pharyngeal mucosa</td>
<td>2 – 8 ml up to 3 times daily</td>
<td>WHO monographs, 2002</td>
</tr>
<tr>
<td></td>
<td>Dry cough and oral or pharyngeal irritation</td>
<td>2-8 ml up to a daily dose equivalent to 15 g of the drug</td>
<td>ESCOP monographs, 2003</td>
</tr>
<tr>
<td>Syrup</td>
<td>Irritation of the oral and pharyngeal mucosa and associated dry cough.</td>
<td>Single dose 10 g</td>
<td>Blumenthal e, 1998</td>
</tr>
<tr>
<td></td>
<td>Throat irritation</td>
<td>single dose: 10 ml</td>
<td>Blumenthal et al., 2000</td>
</tr>
<tr>
<td>Herbal preparation</td>
<td>Documented use / Traditional use</td>
<td>Pharmaceutical form</td>
<td>Reference</td>
</tr>
<tr>
<td>--------------------</td>
<td>----------------------------------</td>
<td>----------------------</td>
<td>-----------</td>
</tr>
<tr>
<td></td>
<td>Irritation of oral or pharyngeal mucosa and associated dry cough</td>
<td>Adults single dose 3 – 5 g; children 1-4 years 2 – 4 g, children 4 – 10 years 4 – 6 g, children 10 – 16 years 6-10 g</td>
<td>Dorsch et al., 2002</td>
</tr>
<tr>
<td>Syrup, DAC</td>
<td>Against cough</td>
<td>5-10 ml several times daily</td>
<td>Deutscher Arzneimittel-Codex, 1979, 2004</td>
</tr>
<tr>
<td>Syrup Farmakopea Polska 2002</td>
<td>No information</td>
<td>Single dose 10 – 30 g</td>
<td>Farmakopea Polska 2002</td>
</tr>
<tr>
<td>Liquid extract 1:1, extraction solvent ethanol 25% (V/V)</td>
<td>Gastritis, gastric and peptic ulceration, enteritis; inflammation of the mouth and pharynx, respiratory catarrh with irritating cough; cystitis</td>
<td>2-5 ml 3 times daily</td>
<td>British Herbal Pharmacopoeia 1983</td>
</tr>
<tr>
<td></td>
<td>for the treatment of respiratory catarrh and cough, peptic ulceration, inflammation of the mouth and pharynx, enteritis, cystitis, urethritis, and urinary calculus</td>
<td>2-5 ml 3 times daily</td>
<td>Barnes et al., 2002; Newal et al., 1996</td>
</tr>
<tr>
<td>Liquid extract 1:1,</td>
<td>Reference to the Commission E Monograph,</td>
<td>2-5 ml up to 3 times daily</td>
<td>Blumenthal et al.,</td>
</tr>
<tr>
<td>Herbal preparation</td>
<td>Documented use / Traditional use</td>
<td>Pharmaceutical form</td>
<td>Reference</td>
</tr>
<tr>
<td>----------------------------------------</td>
<td>---------------------------------------------------------------------------------------------------</td>
<td>--------------------------------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>extraction solvent not specified</td>
<td>British Herbal Compendium, ESCOP monograph, German Standard Licence</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dry extract 3.5-5:1, extraction solvent not specified</td>
<td>Reference to the Commission E Monograph, British Herbal Compendium, ESCOP monograph, German Standard Licence</td>
<td>0.4-0.6 g up to 3 times daily</td>
<td>Blumenthal et al., 2000</td>
</tr>
<tr>
<td>Soft extract 2.3-3.2:1, extraction solvent not specified</td>
<td>Reference to the Commission E Monograph, British Herbal Compendium, ESCOP monograph, German Standard Licence</td>
<td>0.6-0.9 g up to 3 times daily</td>
<td>Blumenthal et al., 2000</td>
</tr>
</tbody>
</table>
| Tincture 1 : 5, extraction solvent ethanol 25% (V/V) | Internally: for gastroenteritis, peptic or duodenal ulceration, common and ulcerative colitis and enteritis.  
|                                            | Topically: as mouthwash or gargle for inflammation of the pharynx                             | 5 – 15 ml 3 times daily              | Bradley, 1992           |
| Tincture 1 : 5, extraction solvent not specified | Reference to the Commission E Monograph, British Herbal Compendium, ESCOP monograph, German Standard Licence | 10 – 25 ml up to 3 times daily        | Blumenthal et al., 2000 |
| Ointment 5% powdered Althaea root in usual ointment base | Varicose and thrombotic ulcers                                                                    | Three time daily                      | British Herbal Pharmacopoeia 1983 |
| 5-10% preparations in an ointment or cream | Furunculosis, eczema, dermatitis                                                                  | Three time daily                      | Bradley, 1992           |
2.3. Overall conclusions on medicinal use

Traditional use of *Althaea officinalis* (L.), root in the form of macerate is well documented in a number of literature sources. Aqueous extracts of the herbal substances are used in the Member States for at least 30 years. Based on information provided by the National Competent Authorities in the overview of the marketed products and literature data the following herbal preparations fulfil the criteria set in Directive 2001/83/EC for at least 30 years of the medicinal use:

Table 4: Overview of evidence on period of medicinal use

<table>
<thead>
<tr>
<th>Herbal preparation</th>
<th>Indication</th>
<th>Posology, Strength</th>
<th>Period of medicinal use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Comminuted herbal substance for macerate preparation</td>
<td>Sore throat and upper respiratory complaints</td>
<td>Herbal tea: 10 g of the comminuted herbal substance in 200 ml of water as a macerate Single dose 60 ml 2 – 3 times daily</td>
<td>Poland more than 30 years</td>
</tr>
<tr>
<td></td>
<td>Irritation of the oral and pharyngeal mucosa and associated dry cough</td>
<td>Herbal tea prepared from up to 6g/daily (6g divided in two or three portions)</td>
<td>Spain before 1973</td>
</tr>
<tr>
<td></td>
<td>Supportive treatment of respiratory catarrhs associated with irritation of respiratory organs, cough, and hoarseness; inflammations of urogenital and gastrointestinal tracts (cystitis, nephrolithiasis, enteritis, diarrhoea, gastric and duodenal ulcers), topically – as a gurgle in mouth inflammations; eye and skin inflammations; burns; furunculosis and carbunculosis</td>
<td>Daily dose: macerate prepared from 4 spoons of Marshmallow root (17.2 g)</td>
<td>Madaus, 1938</td>
</tr>
<tr>
<td></td>
<td>No information</td>
<td>Adults: average single dose: 0.50-1.00; average daily dose: 1.5-5.0 g</td>
<td>VI&lt;sup&gt;th&lt;/sup&gt; Hungarian Pharmacopoeia, 1970</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Children 1 year single dose 0.12 g, daily dose 1.0 g; children 3 years single dose 0.2, daily dose 1.0 g; children 6 years single dose 0.3 g, daily dose 1.5 g; children 9 years single dose 0.5, daily dose</td>
<td></td>
</tr>
<tr>
<td>Herbal preparation Pharmaceutical form</td>
<td>Indication</td>
<td>Posology, Strength</td>
<td>Period of medicinal use</td>
</tr>
<tr>
<td>----------------------------------------</td>
<td>------------</td>
<td>--------------------</td>
<td>------------------------</td>
</tr>
<tr>
<td></td>
<td>A demulcent and emollient, for irritation and inflammation of the mucous membranes of the mouth and pharynx. The boiled and bruised root has been used as a poultice.</td>
<td>2.5 g; children 12 years single dose 0.6 g, daily dose 3.0 g; children 15 years single dose 0.8 g, daily dose 4.0 g</td>
<td>Martindale Extra Pharmacopoeia, 1977</td>
</tr>
<tr>
<td></td>
<td>Gastritis, gastric and peptic ulceration, enteritis; inflammation of the mouth and pharynx, respiratory catarrh with irritating cough; cystitis; locally – varicose and thrombotic ulcers</td>
<td>2-5 g or by cold extraction</td>
<td>British Herbal Pharmacopoeia, 1983</td>
</tr>
<tr>
<td>Syrup, BPC 1949</td>
<td>As a demulcent and emollient for the treatment of bronchitis</td>
<td>2 – 8 ml</td>
<td>British Pharmaceutical Codex, 1949</td>
</tr>
<tr>
<td></td>
<td>A demulcent and emollient, for irritation and inflammation of the mucous membranes of the mouth and pharynx</td>
<td>2 – 8 ml</td>
<td>Martindale Extra Pharmacopoeia, 1977</td>
</tr>
<tr>
<td></td>
<td>Inflammation of the mouth and pharynx, respiratory catarrh with irritating cough</td>
<td>2 – 8 ml 3 times daily</td>
<td>British Herbal Pharmacopoeia, 1983</td>
</tr>
<tr>
<td></td>
<td>Traditional medicinal product used as a means of soothing the symptoms of irritation of oral and throat mucosa and accompanying cough.</td>
<td>100g of syrup contains macerate of 2 parts of <em>Althaea officinalis</em>, radix, with 40 parts of water + 1 part of ethanol 96%</td>
<td>National authorisation, 05.07.1996, based</td>
</tr>
<tr>
<td>Herbal preparation</td>
<td>Indication</td>
<td>Posology, Strength</td>
<td>Period of medicinal use</td>
</tr>
<tr>
<td>-------------------------------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------</td>
</tr>
<tr>
<td>Syrup Farmakopea Polska 2002</td>
<td>Traditional herbal medicinal product used for relieve of symptoms of upper respiratory tract irritations with accompanying cough.</td>
<td>Dosage: children 3-6 years of age 5 ml up to 4 times daily, children 6-12 years of age 5 ml up to 5 times daily, adolescents and adults 10 ml 3 – 5 daily. No restriction of therapy duration.</td>
<td>on Polish Pharmacopoeia III 1954. TU, 2015, Poland</td>
</tr>
<tr>
<td>Syrup Österreichisches Arzneibuch 1981</td>
<td>No information</td>
<td>No information</td>
<td>Poland, traditional registration, 2014</td>
</tr>
<tr>
<td>Syrup</td>
<td>A demulcent for symptomatic treatment of dry irritable cough</td>
<td>Syrup prepared from the macerate (34.9 g) of 2 g Althaeae radix The dosage is 2-8 ml. No information on frequency of use is available.</td>
<td>Lithuania, more than 100 years</td>
</tr>
<tr>
<td>Syrup Československý lékopis 1954</td>
<td>No information</td>
<td>No information</td>
<td>Československý lékopis, 1954</td>
</tr>
<tr>
<td>Liquid extract 1:1, extraction solvent ethanol 25% (V/V)</td>
<td>Gastritis, gastric and peptic ulceration, enteritis; inflammation of the mouth and pharynx, respiratory catarrh with irritating cough; cystitis</td>
<td>2-5 ml 3 times daily</td>
<td>British Herbal Pharmacopoeia, 1983</td>
</tr>
<tr>
<td>Liquid extract of Althaeae radix (1:19,5-23,5), extraction solvent: water</td>
<td>Irritations of the mucosa in the oropharynx and therewith associated hacking dry cough.</td>
<td>Syrup, 100g (=76,44ml) syrup contains 35,610g liquid extract Adolescents and adults &gt; 12: single dose 10 ml syrup corresponds to 4.6 g</td>
<td>Germany, WEU, at least since 1976 Netherlands, TU 2013</td>
</tr>
<tr>
<td>Herbal preparation</td>
<td>Indication</td>
<td>Posology, Strength</td>
<td>Period of medicinal use</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------------</td>
<td>---------------------------------------</td>
</tr>
<tr>
<td>Dry extract of Althaeae radix (3-9:1), extraction solvent: water</td>
<td>Traditional herbal medicinal product for use as a demulcent preparation for the symptomatic treatment of oral or pharyngeal irritation and associated dry cough.</td>
<td>liquid extract, 3-6 times daily, Children between 6 and 12 years of age: single dose 5 ml syrup corresponds to 2.3 g liquid extract, 5 times daily, Children between 3 and 5 years of age: single dose 4 ml corresponds to 1.9 g liquid extract, 4 times daily, Children between 1 and 2 years of age: single dose 3 ml corresponds to 1.4 g liquid extract, 4 times daily</td>
<td>Germany TU 2013</td>
</tr>
<tr>
<td>Ointment 5% powdered Althaea root in usual ointment base</td>
<td>Varicose and thrombotic ulcers</td>
<td>Three time daily</td>
<td>British Herbal Pharmacopoeia, 1983</td>
</tr>
</tbody>
</table>
The following indications are proposed for the European Union Monograph

Traditional herbal medicinal product for use as a demulcent preparation for the symptomatic treatment of oral or pharyngeal irritation and associated dry cough for the symptomatic relief of mild gastrointestinal discomfort

The topical use is mentioned in many references (WHO monograph, 2002; Barnes et al., 2002; Newal et al., 1996; Bäumler, 2007; Hänsel et al., 1993; Gruenwald et al., 1998; Martindale, 1977; BPC 1949, Bradley, 1992) for treatment of skin inflammations, ulcers, abscesses, burns, furuncles, carbuncles. Althaeae radix is described to be used in the form of ointments, poultices, cataplasms or fomentations; however, no sufficient information on the preparations has been found.

Based on the literature data and information received from the Member States, the following posologies are suggested:

For indication 1)

Oral use

Comminuted herbal substance

Adolescents, adults and elderly: Herbal tea: 0.5 - 3 g of the comminuted herbal substance in 150 ml of water as a macerate several times daily; maximum daily dose: 15 g
Children 6-12 years of age: Herbal tea: 0.5 – 1.5 g of the comminuted herbal substance in 150 ml of water as a macerate 3 times daily; daily dose: 1.5–4.5 g
Children 3-5 years of age: Herbal tea: 0.5 – 1.0 g of the comminuted herbal substance in 150 ml of water as a macerate 3 times daily; daily dose: 1.5–3.0 g

Liquid extract (DER 1:19.5-23.5), extraction solvent water

Adolescents, adults and elderly: single dose: 4.6 g 3 – 6 times daily; daily dose: 13.8 – 27.6 g
Children 6-12 years of age: single dose: 2.3 g 5 times daily; daily dose: 11.5 g
Children 3-5 years of age: single dose: 1.9 g 4 times daily; daily dose: 7.6 g

Macerate for preparation of syrup

Adolescents, adults and elderly: single dose: macerate amount corresponding to 0.21 to 0.87 g of the herbal substance (10 – 15 ml of syrup) 3 – 5 times daily; daily dose: macerate amount corresponding to 0.63 to 2.9 g of the herbal substance (30 – 50 ml of syrup)
Children 6-12 years of age: single dose: macerate amount corresponding to 0.1 to 0.29 g of the herbal substance (5 ml of syrup) 3 - 5 times daily; daily dose: macerate amount corresponding to 0.32 to 1.45 g of the herbal substance (15 – 25 ml of syrup)
Children 3-6 years of age: single dose: macerate amount corresponding to 0.1 to 0.29 g of the herbal substance (5 ml of syrup) up to 4 times daily; daily dose: macerate amount corresponding to 0.21 to 1.16 g of herbal substance (10 – 20 ml of syrup)

Liquid extract (DER 1:1), extraction solvent ethanol 25% (V/V)

Adults and elderly: single dose: 2 – 5 ml 3 times daily; daily dose: 6 – 15 ml

Oromucosal use

Dry extract (3-9:1), extraction solvent water

Adolescents, adults and elderly: single dose: 160 mg several times daily; maximum daily dose: 1.6 g
Children 6-12 years of age: single dose: 160 mg 3 times daily; daily dose: 480 mg
For indication 2)

Comminuted herbal substance

Adolescents, adults and elderly: Herbal tea: 3 - 5 g of the comminuted herbal substance in 150 ml of water as a macerate 3 times daily; maximum daily dose: 15 g

Liquid extract (DER 1:1), extraction solvent ethanol 25% (V/V)

Adults and elderly: single dose: 2 – 5 ml 3 times daily; daily dose: 6 – 15 ml

3. Non-Clinical Data

3.1. Overview of available pharmacological data regarding the herbal substance(s), herbal preparation(s) and relevant constituents thereof

3.1.1. Primary pharmacodynamics

In Franz, 1989 information that the mucilage covers the mucosa with a kind of protecting layer which protects it from local irritation has been found. The only non-clinical study supporting this statement is an in vitro study of bioadhesive effects of polysaccharides isolated from Althaeae radix on isolated porcine buccal membrane by Schmidgall (see information below).

Bioadhesive effects

In vitro:

Polysaccharides

Purified polysaccharides (carbohydrates content >95%) from *Althaea officinalis* root were investigated for bioadhesive effect on isolated porcine buccal membranes. Polysaccharides from Marshmallow root showed a moderate adhesion to epithelial tissue. The adhesive effect was concentration dependent. This *ex vivo* system does not completely reflect the physiological status of the epithelia. Especially the naturally occurring mucus layer, originating from interaction of saliva or endogenously secreted glycoproteins with the epithelia can cause slightly different conditions (Schmidgall et al., 2000).

Antitussive effect

In vitro

Water extract

Weak inhibition (17.1 %) of mucociliary transport in ciliated epithelium isolated from frog oesophagus has been observed after addition of 200 μl of marshmallow root macerate (6.4 g/140 ml) (Müller-Limroth and Fröhlich, 1980).

Water extract/polysaccharide

Lyophilised aqueous extract from marshmallow roots (DER 1:20) (AE) in concentrations 1 and 10 g/mL had a stimulating effect on cell viability and proliferation of epithelial KB cells. Raw polysaccharide mixture (RPS) isolated from the same extract by precipitation with ethanol stimulated (at concentrations 1 and 10 g/mL) cell vitality of epithelial cells significantly without triggering the cells into higher proliferation status. Neither AE nor RPS had any effect on fibroblasts. FITC (fluorescein isothiocyanate)-labelled RPS was shown to be internalised into epithelial cells, but not into fibroblasts. FITC-RPS was shown to form bioadhesive layers on the cell surface of dermal fibroblasts. Microarray analysis indicated an up-regulation of genes related to cell adhesion proteins, growth regulators, extracellular matrix, cytokine release and apoptosis. The authors concluded that extracts and polysaccharides from the roots of *A. officinalis* are effective stimulators of cell physiology of epithelial
cells which can prove the traditional use of Marshmallow preparations for treatment of irritated mucous membranes within tissue regeneration. (Deters et al., 2010, Ziffel et al. 2009)

**In vivo**

**Extract/polysaccharides**

An extract from marshmallow root (type of extract was not specified) and isolated mucilage polysaccharide were tested for antitussive activity in unanaesthetised cats of both sexes at doses of 50 to 100 mg/kg body weight administrated orally. The cough was induced by mechanical stimulation. The antitussive effect of marshmallow root extract and isolated mucilage polysaccharide was compared with the cough-suppressing effects of Althaea syrup (1000 mg/kg), prenoxidazine (30 mg/kg), dropropizine (100 mg/kg) and codeine (10 mg/kg). Both the extract and isolated polysaccharide significantly reduced the intensity and the number of cough efforts from laryngopharyngeal and tracheobronchial areas. The root extract was less effective than the isolated polysaccharide. The antitussive activity was found to be lower than that of codeine, but higher than those of the comparative non-narcotic drugs (prenoxidazine, dropropizine) (Nosálová et al., 1992, 1992a and 1993).

Antitussive effect of the polysaccharide rhamnogalacturonan isolated from roots of *Althaea officinalis* (25 and 50 mg.kg⁻¹ b.w. administered orally) has been studied in an *in vivo* study with sensitized (ovalbumin) and unsensitized male guinea pigs. The cough of guinea pigs was induced by 0.3 M citric acid aerosol. The polysaccharide dose dependently inhibited cough reflex in unsensitized animals. The authors concluded that polysaccharide isolated from *Althaea officinalis* root possess dose-dependent cough suppressive effect in unsensitized animals. The antitussive activity of the higher dose of rhamnogalacturonan was comparable to the antitussive activity of codeine (10 mg.kg⁻¹ b.w. administered orally) in unsensitized animals. Bronchodilatation is not involved in mechanism of antitussive action. Allergic airways inflammation shortens the duration of rhamnogalacturonan antitussive effect which was confirmed by histopathological evaluation. (Sutovská et al., 2011)

Possible mechanism of dose-dependent cough suppressive effect described above has been studied in an additional *in vitro* and *in vivo* study with guinea pigs and with guinea pigs tracheal smooth muscle strips and lung tissue strips. Reactivity of the airways smooth muscle was not significantly affected by rhamnogalacturonan and thus bronchodilatatory activity did not participate in the cough suppression effect of the polysaccharide. Moreover, the cough suppression effect of the polysaccharide was not significantly modified by pretreatment of K⁺ATP ion channels with selective antagonist (glibenclamide in the dose 3 mgPkg b.w. intraperitoneally 20 minutes before perorally applied rhamnogalacturonan in the dose 50 mg/kg b.w.) and therefore activation of this type of ion channels is not involved in the mechanism of rhamnogalacturonan cough suppression ability. On the contrary, pretreatment of animals with selective 5-HT₂ receptors antagonist (ketanserin in the dose 1 mg/kg b.w. administered intraperitoneally or directly into the nasopharynx in the dose 20 μL of 200 μM solution) significantly decreased rhamnogalacturonan antitussive efficacy. From this point of view it seems that the cough suppression effect of the polysaccharide is associated with the serotonergic 5-HT₂ receptor´s function. (Šutovská et al., 2009)

**Anti-inflammatory activity**

**In vivo**

**Water extract**

An ointment containing an aqueous marshmallow root extract (20%) applied topically to the external ear of rabbits reduced irritation induced by UV irradiation or by tetrahydrofurfurly alcohol. The ointment has been compared to pure dexamethasone 0.05% ointment and a combined marshmallow and dexamethasone product. The anti-inflammatory effect of marshmallow ointment was lower than
that of a dexamethasone ointment. The combined product had higher anti-inflammatory effect than the ointments with the individual ingredients (Beaune and Balea 1966).

**Ethanol extract**

However, with a dry extract prepared from 100 g of the plant material and 300 ml of 80% ethanol administered orally to male Wistar rats (100 mg/kg b.w.), no inhibition of carrageenan induced rat paw oedema has been proved (Mascolo et al., 1987).

**Isolated compounds**

Hypolaetin 8-glucoside has been tested for its anti-inflammatory, analgesic and anti-ulcer activity in rats. The flavonoid (30, 60 and 90 mg/kg i.p.) was more potent than phenylbutazone (30, 60 and 90 mg/kg i.p.) in suppressing the acute phase of adjuvant carrageenan-induced inflammation but had less effect in the prolonged inflammatory phase. In contrast to phenylbutazone, it did not cause gastric erosions. Analgesic activity of hypolaetin 8-glucosid has been found to be lower than the one of phenylbutazone. Anti-ulcer activity has been compared to cimetidine (40, 70 and 100 mg/kg i.p.). Both substances prevented the formation of cold-restraint induced gastric lesions, but cimetidine was more potent. Hypolaetin 8-glucoside was also more potent than troxerutin (both at the doses of 100, 200, 300 and 400 mg/kg s.c.) in inhibiting histamine-induced capillary permeability in rats (Villar et al., 1984, Villar et al., 1987, Alcaraz et al., 1989).

**Tissue regeneration**

**In vitro**

Warer extract/polysaccharides

Lyophilised aqueous extract from marshmallow roots (DER 1:20) (AE) in concentrations 1 and 10 g/mL had a stimulating effect on cell viability and proliferation of epithelial KB cells. Raw polysaccharide mixture (RPS) isolated from the same extract by precipitation with ethanol stimulated (at concentrations 1 and 10 µg/mL) cell vitality of epithelial cells significantly without triggering the cells into higher proliferation status. Neither AE nor RPS had any effect on fibroblasts. FITC (fluoresceinisothiocyanate)-labelled RPS was shown to be internalised into epithelial cells, but not into fibroblasts. FITC-RPS was shown to form bioadhesive layers on the cell surface of dermal fibroblasts. Microarray analysis indicated an up-regulation of genes related to cell adhesion proteins, growth regulators, extracellular matrix, cytokine release and apoptosis. The authors concluded that extracts and polysaccharides from the roots of *A. officinalis* are effective stimulators of cell physiology of epithelial cells. (Deters et al., 2010, Ziffel et al. 2009)
Table 5: Overview of the main non-clinical data/conclusions

<table>
<thead>
<tr>
<th>Herbal preparation tested</th>
<th>Posology</th>
<th>Experimental model</th>
<th>Reference</th>
<th>Main non-clinical conclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cold macerate 6.4 g/140 ml</td>
<td>200 μl applied on ciliated epithelium isolated from frog oesophagus</td>
<td><em>In vitro</em></td>
<td>Müller-Limmroth and Fröhlich 1980</td>
<td>Weak inhibition of mucociliary transport</td>
</tr>
<tr>
<td>Water extract (DER 1:20)</td>
<td>1 and 10 mg/L</td>
<td><em>In vitro</em></td>
<td>Deters <em>et al.</em>, 2010, Ziffel <em>et al.</em> 2009</td>
<td>Stimulating effect on cell viability and proliferation of epithelial KB cells, no effect on fibroblasts</td>
</tr>
<tr>
<td>Raw polysaccharide mixture</td>
<td>1 and 10 mg/L</td>
<td><em>In vitro</em></td>
<td>Deters <em>et al.</em>, 2010, Ziffel <em>et al.</em> 2009</td>
<td>Stimulation of cell vitality of epithelial cells without triggering the cells into higher proliferation status, no effect on fibroblasts; up-regulation of genes related to cell adhesion proteins, growth regulators, extracellular matrix, cytokine release and apoptosis.</td>
</tr>
<tr>
<td>Extract (type of extract not specified) and polysaccharide</td>
<td>50 – 100 mg/kg bw Oral administration (cats)</td>
<td><em>In vivo</em></td>
<td>Nosálová <em>et al.</em>, 1992, 1992a and 1993</td>
<td>Reduction of intensity and cough efforts from laryngopharyngeal and tracheobronchial areas; extract less effective than isolated polysaccharide; antitussive activity lower than codeine but higher than prenodoxazine, dropropizine</td>
</tr>
<tr>
<td>Purified polysaccharides</td>
<td>1 ml of 1% solution/cm² of mucous membrane</td>
<td><em>In vitro</em></td>
<td>Schmidgall <em>et al.</em>, 2000</td>
<td>Moderate bioadhesive effect</td>
</tr>
<tr>
<td>Isolated rhamnogalacturonan</td>
<td>25 and 50 mg.kg⁻¹ b.w.; oral administration (guinea pigs)</td>
<td><em>In vivo</em></td>
<td>Sutovska <em>et al.</em>, 2011</td>
<td>Dose-dependent cough suppressive effect in unsensitised animals</td>
</tr>
<tr>
<td>Isolated</td>
<td>50 mg.kg⁻¹ b.w.; oral</td>
<td><em>In vitro and in vivo</em></td>
<td>Šutovská <em>et al.</em>,</td>
<td>Dose-dependent cough suppressive effect</td>
</tr>
<tr>
<td>Herbal preparation tested</td>
<td>Posology</td>
<td>Experimental model</td>
<td>Reference</td>
<td>Main non-clinical conclusions</td>
</tr>
<tr>
<td>---------------------------</td>
<td>----------</td>
<td>--------------------</td>
<td>-----------</td>
<td>------------------------------</td>
</tr>
<tr>
<td>rhamnogalacturonan</td>
<td>administration (guinea pigs)</td>
<td><em>vivo</em></td>
<td>2009</td>
<td>not significantly modified by pretreatment of K\textsubscript{ATP} ion channels with selective antagonist but significantly decreased after pretreatment with selective 5-HT\textsubscript{2} receptors antagonist</td>
</tr>
<tr>
<td>Aqueous marshmallow root extract (20%)</td>
<td></td>
<td><em>In vivo</em></td>
<td>Beaune and Balea, 1966</td>
<td>rabbits reduced irritation induced by UV irradiation or by tetrahydrofurfuryl alcohol</td>
</tr>
<tr>
<td>Dry extract prepared from 100 g of the plant material and 300 ml of 80% ethanol</td>
<td>100 mg/kg b.w., oral administration (rats)</td>
<td><em>In vivo</em></td>
<td>Mascolo et al., 1987</td>
<td>no inhibition of carrageenan induced rat paw oedema has been proved</td>
</tr>
<tr>
<td>Hypolaetin 8-glucoside</td>
<td>30, 60 and 90 mg/kg, intraperitoneal administration (rats)</td>
<td><em>In vivo</em></td>
<td>Villar et al., 1984; Villar et al.; 1987; Alcaraz et al., 1989</td>
<td>more potent than phenylbutazone in suppressing the acute phase of adjuvant carrageenan-induced inflammation but had less effective in the prolonged inflammatory phase. It did not cause gastric erosions. Analgesic activity lower than phenylbutazone. Anti-ulcer activity - prevented the formation of cold-restraint induced gastric lesions, less potent than cimetidine. was more potent. More potent than troxerutin in inhibiting histamine-induced capillary permeability in rats</td>
</tr>
</tbody>
</table>
3.1.2. Secondary pharmacodynamics

**Antimicrobial activity**

**In vitro**

**Water and other extracts**

A 10% decoction and methanolic extract prepared by exhaustive extraction from marshmallow root has been shown to possess an inhibiting activity able to diminish significantly the periodontal pathogens resident in the oral cavity (Porphyromonas gingivalis, Prevotella spp., Actinomyces odontolyticus, Veillonella parvula, Eikenella corrodens, Fusobacterium nucleatum, Peptostreptococcus spp., Capnocytophaga gingivalis). The methanol extract was active against P. gingivalis, Prevotella spp. and Actinomyces spp. (9 of 12 strains had a minimum inhibitory activity (MIC) ≤ 3125 mg/L). The decoction had higher MIC values (4096 – 8192 mg/L). The strains of C. gingivalis, V. parvula, E. corrodens and Peptostreptococcus spp. were inhibited by a MIC = 8192 mg/L (methanol extract) resp. ≥ 1684 mg/L (decoction), those of F. nucleatum by a MIC ≥ 1684 mg/L (both methanol extract and decoction). (Iauk et al., 2003).

**Immunomodulatory activity**

**In vivo**

**Polysaccharides**

Marshmallow mucilage polysaccharides administered intraperitoneally to mice at a dose of 10 mg/kg produced a 2.2-fold increase in phagocytic activity of macrophages in the carbon-clearance test (Wagner and Proksch, 1985).

**Hypoglycaemic activity**

**In vivo**

**Polysaccharides**

Isolated marshmallow root polysaccharide (Althaea-mucilage-O) administered intraperitoneally to non-diabetic mice at doses of 10, 30 and 100 mg/kg of body weight has been demonstrated to reduce significantly blood glucose (74%, 81% and 65% respectively) of the control level after 7 hours; after 24 hours only weak activity has been observed (93, 90 and 89% respectively) (Tomoda et al., 1987; NMCD, 2008).

Hypoglycaemic activity of water-soluble mucilage obtained from Althaeae radix administrated to non-diabetic mice has also been reported (Perez et al., 1998).

**Other activities**

**In vitro**

**Water extract**

Antioxidant activity (DPPH radical scavenging activity) of polysaccharides extracted from *A. officinalis* roots in various experimental operating conditions (extraction temperature 10 – 90 °C; particle size 6-24 mm and water to solid (W/S) ratio 10 – 50) has been studied. The optimum conditions to maximize yield (10.80%) and antioxidant activity (84.09%) were extraction temperature 60.90 °C, extraction time 12.01 h, particle size 12.0 mm and W/S ratio of 40. (Ghavi, 2015)

**Other extract**

An extract (extraction medium 45 % 1,3-butylene glycol solution) of marshmallow root was found to inhibit intracellular calcium mobilisation in normal human melanocytes activated by endothelin-1, and
to strongly inhibit endothelin-1-induced proliferation of melanocytes. The extract can diminish the physiological effect of endothelin-1 on normal human melanocytes following UVB irradiation (Kobayashi et al., 2002).

Cytoprotective effects of methanol/aqueous (1:1, V/V) polysaccharide depleted extract from Marshmallow roots (containing very polar, low-molecular, water soluble compounds) have been studied in an in vitro investigation on keratinocytes by MTT-assay demonstrated that neither the extract of marshmallow roots nor the single compounds had any negative influence. As result of these data cytoprotective effects of extracts of Althaea officinalis L. could be explainable besides the proven active mucilage polysaccharides (Böker et al., 2012)

3.1.3. Safety pharmacology

No data available.

3.1.4. Pharmacodynamic interactions

It is mentioned in some literature sources (Barnes et al., 2002, Hänsel et al., 1993) that absorption of concomitantly administered medicines can be delayed due to mucilage protecting layer. For this reason the product should not be taken ½ to 1 hour before or after intake of other medicinal products. However, no tests on humans or animals were performed to confirm delayed absorption.

3.1.5. Conclusions

Marshmallow root is traditionally used as a demulcent preparation

- for the symptomatic treatment of oral or pharyngeal irritation and associated dry cough
- for the symptomatic relief of mild gastrointestinal discomfort

Marshmallow root preparations and isolated polysaccharides have been investigated in several pharmacological in vitro and in vivo studies demonstrating several effects. A direct correlation of the test results (kind of extract, route of administration in vitro vs. in vivo) with the clinical situation is not possible. The reported pharmacological effects are not considered contradictory to the oral and oromucosal traditional use of herbal preparations of Marshmallow root as a demulcent for the symptomatic treatment of irritations of oral and pharyngeal mucosa with associated dry cough.

A study with isolated hypolaetin 8-glucoside can be considered supporting the use of the herbal substance and preparation thereof for the symptomatic treatment of mild gastrointestinal discomfort; moreover, this indication is considered plausible for traditional use of the herbal substance and preparations thereof as the mucilage contained in the products makes a kind of protecting layer on the mucosa which protects it from local irritation.

In the literature there is a hypothesis that absorption of concomitantly administrated medicinal products can be delayed due to mucilage protecting layer. As this hypothesis was not confirmed neither in non-clinical or clinical studies, this information has not been included in the section 4.5 ‘Interactions with other medicinal products and other forms of interaction’, however, it has been introduced in the section 4.4 ‘Special warnings and precautions for use’ as a precautionary measure.

3.2. Overview of available pharmacokinetic data regarding the herbal substance(s), herbal preparation(s) and relevant constituents thereof

No information available concerning pharmacokinetic.
3.3. Overview of available toxicological data regarding the herbal substance(s)/herbal preparation(s) and constituents thereof

3.3.1. Single dose toxicity

Mice were per orally treated with the polysaccharide extract prepared from roots of *Althaea officinalis* (extract from 200 g of roots and 1 l of purified water, purified and dried) in doses 2000, 3000, 4000 and 5000 mg/kg b.w. Animals were observed daily for clinical signs of mortality over a period of two week following the treatment. The acute toxicity LD50 of *A. officinalis* extract in albino mice was found to be above 5000 mg/kg. (Benbassat et al., 2013)

3.3.2. Repeat dose toxicity

No data available.

3.3.3. Genotoxicity

An aqueous extract from marshmallow (no details on plant part used, and DER available) in concentrations 31.6, 100, 316, 1000, 25000 and 5000 μg/plate was proved non-mutagenic in the reverse mutation assay with the *Salmonella typhimurium* strains TA 98, TA 100, TA 1535, TA 1537 and TA 100 with and without metabolic activation. (BSL BIOSERVICE Study No.: 131997, 2013)

3.3.4. Carcinogenicity

No data available

3.3.5. Reproductive and developmental toxicity

No data available

3.3.6. Local tolerance

No data available

3.3.7. Other special studies

No data available

3.3.8. Conclusions

Single dose toxicity tests with the dry aqueous extract prepared from roots of *Althaea officinalis* (extract from 200 g of roots and 1 l of purified water indicate the following data: no lethality was observed at doses up to 5 g per kg body weight after oral administration in mice.

An aqueous extract from marshmallow was proved non-mutagenic in the reverse mutation assay with the *Salmonella typhimurium* strains TA 98, TA 100, TA 1535, TA 1537 and TA 100 with and without metabolic activation. However the herbal preparation used in the test was not sufficiently described and therefore results of the test cannot be taken into consideration.

Tests on reproductive toxicity and carcinogenicity have not been performed.
3.4. **Overall conclusions on non-clinical data**

Despite non-clinical data on several activities of the water extract and/or substances isolated thereof exist; a direct correlation of the test results (kind of extract, route of administration *in vitro* vs. *in vivo*) with the clinical situation is not possible. The reported pharmacological effects are not considered contradictory to the oral and oromucosal traditional use of herbal preparations of Marshmallow root as a demulcent for the symptomatic treatment of irritations of oral and pharyngeal mucosa with associated dry cough and for the symptomatic relief of mild gastrointestinal discomfort. None of the reported pharmacological studies constitute any cause for safety concern.

Specific data on pharmacokinetics and interactions are not available.

A negative test on genotoxicity has been provided; however the preparation of the test was not sufficiently described and therefore results of the test cannot be taken into consideration.

Tests on reproductive toxicity and carcinogenicity have not been performed. As there is no information on reproductive and developmental toxicity the use during pregnancy and lactation cannot be recommended.

4. **Clinical Data**

4.1. **Clinical pharmacology**

4.1.1. **Overview of pharmacodynamic data regarding the herbal substance(s)/preparation(s) including data on relevant constituents**

No data available

4.1.2. **Overview of pharmacokinetic data regarding the herbal substance(s)/preparation(s) including data on relevant constituents**

Due to lack of data, no conclusion can be drawn.

4.2. **Clinical efficacy**

4.2.1. **Dose response studies**

No data available

4.2.2. **Clinical studies (case studies and clinical trials)**

Clinical studies available regarding indication a) (a demulcent preparation for the symptomatic treatment of oral or pharyngeal mucosa irritation and associated dry cough) are the post marketing surveillance study and the retrospective observational study in children mentioned below in section 4.2.3.

Other clinical study available is a double-blind placebo-controlled clinical trial with 63 patients (18 men and 45 women) of Iranian origin studying the effect of *Althaea officinalis* on dry cough associated with ACE inhibitors. Thirty patients were treated with 40 mg of *Althaea officinalis* in a form of drops (20 drops three times daily) and 30 with placebo. No details on the composition of the Althaea preparation have been given. Duration of treatment was four weeks. Three patients were excluded from the study.
for non-compliance. The tested parameters were cough score (0-4) and spirometry before and after intervention.

The mean cough score in the Althaea group was 2.66±0.95 before the intervention and 1.23±1 after the treatment (statistically significant reduction, P<0.05). No significant change was found in the placebo group (2.7±0.79 before the treatment and 2.33±0.84 after the treatment) (Rouhi and Ganji 2007).
Table 6: Clinical studies on humans, in irritated mucosa and associated dry cough

<table>
<thead>
<tr>
<th>Type</th>
<th>Study</th>
<th>Test Product(s)</th>
<th>Number of Subjects</th>
<th>Type of Subjects</th>
<th>Outcomes</th>
<th>Statistical analysis</th>
<th>clinical relevance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment of ACE inhibitors induced dry cough</td>
<td>double-blind placebo controlled study</td>
<td>40 mg of <em>Althaea officinalis</em> in a form of drops (20 drops three times daily); no further details on composition of <em>Althaea</em> preparation duration: 4 weeks</td>
<td>63 patients (18 men; 45 women; 3 patients excluded for non-compliance (<em>Althaea</em> group 30 patients, placebo 30 patients)</td>
<td>dry cough associated with ACE inhibitors therapy</td>
<td>Significant cough score reduction, no significant differences in the spirometry parameters</td>
<td>statistically significant reduction, P&lt;0.05</td>
<td>Significant cough score reduction</td>
</tr>
<tr>
<td>Efficacy study</td>
<td>Rouhi and Ganji, 2007</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment of mucous membrane irritation in the mouth and pharynx and associated dry irritating cough</td>
<td>Post-marketing surveillance study</td>
<td>Syrup containing 35.61 g/100 g = 76.45 ml of water extract from Marshmallow root 1: 19.5 – 23.5 2.5-10 ml 4-6 times daily Duration: 3 days in average</td>
<td>313 children (52.4 % girls, 47.6 % boys) Age groups: 0-3 years n = 100; 3-6 years n = 115; 6-12 years n = 98</td>
<td>mucous membrane irritation in the mouth and pharynx and associated dry irritating cough</td>
<td>Symptoms assessed: cough symptoms (cough intensity, cough frequency, extent of coughing during periods of the day), cough related symptoms (disorders in falling asleep and sound sleeping, pain in the neck, pain in the chest) and accompanying symptoms (catarrh, temperature) Efficacy very good to good 84.3%,</td>
<td>none</td>
<td>Results judged by physicians and patients or their parents, no objective measures were made</td>
</tr>
<tr>
<td>Type</td>
<td>Study</td>
<td>Test Product(s)</td>
<td>Number of Subjects</td>
<td>Type of Subjects</td>
<td>Outcomes</td>
<td>Statistical analysis</td>
<td>clinical relevance</td>
</tr>
<tr>
<td>-------------------------</td>
<td>------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>--------------------</td>
<td>------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>----------------------</td>
<td>----------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Treatment of mucous membrane irritation in the mouth and pharynx and associated dry cough</td>
<td>Retrospective observational study</td>
<td>Syrup containing 35.61 g/100 g = 76.45 ml of water extract from Marshmallow root 1 : 19.5 – 23.5 1-5 ml 1-6 times daily Duration: 3-14 days</td>
<td>599 children Age groups: 0-3 months n=61; 3 months -3 years n=128; 3-6 years n= 188; 6-12 years n=222</td>
<td>mucous membrane irritation in the mouth and pharynx and associated dry cough</td>
<td>Efficacy: very good to good ≥90%; satisfactory 4.2%; inadequate 0.3% (2 cases) No adverse effects reported</td>
<td>none</td>
<td>Results judged by physicians and patients or their parents, no objective measures were made</td>
</tr>
</tbody>
</table>

Efficacy and tolerability study 
Bässler, 2005
4.3. Clinical studies in special populations (e.g. elderly and children)

Post-marketing surveillance study

313 children (0-3 years n= 100; 3-6 years n= 115; 6-12 years n=98; the youngest child was 3 months old and the oldest one 12.4 years of age) suffering from mucous membrane irritation in the mouth and pharynx and associated dry irritating cough were investigated to document efficacy and tolerability of syrup from marshmallow roots (containing water extract from Marshmallow root 1 : 19.5 – 23.5 35.61 g/100 g = 76.45 ml ). The following symptoms were evaluated by the physicians and patients or by their parents: cough symptoms (cough intensity, cough frequency, extent of coughing during periods of the day), cough related symptoms (disorders in falling asleep and sound sleeping, pain in the neck, pain in the chest) and accompanying symptoms (catarrh, temperature). The dosage of the medicine was 2.5-10 ml depending on age, four to six times daily. The duration of treatment was three days (73.2 %), in 24.6 % of patients the treatment was continued and 2.2 % of the patients were treated for less than three days. Three children were excluded from the efficacy study due to concomitant medication that was also indicated for dry irritating cough. During the study an adverse event (AE), development of obstructive bronchitis and a serious adverse event (SAE), development of bronchopneumonia resulting in hospitalisation occurred in the age group 0 to 3 years. The causal relationship of the SAE was judged by the physician as "unlikely", the causal relationship of the AE as "unrelated". The coughing intensity and frequency as well as cough-dependent symptoms were strongly reduced after three days. The tolerability of marshmallow root was very good (Fasse et al., 2005).

Retrospective observational study

data from 599 patients were documented by 53 physicians in the present retrospective data analysis of the experience with the application of syrup from marshmallow root water extract from Marshmallow root (containing water extract from marshmallow root 1 : 19.5 – 23.5 35.61 g/100 g = 76.45 ml ) for the indication "mucous membrane irritations in the mouth and pharynx with associated dry cough" in children up to 12 years of age. The children were classified according to four age groups: 61 children 0-3 months of age, 128 children between 3 months and 3 years of age, 188 children between 3 and 6 years of age and 222 children between 6 and 12 years of age. The syrup was given 1-6 times per day in all age groups. 1-5 ml were given per single dose, whereby, on average, both the frequency of administration and, above all, the administered ml per single dose increased with age. The documented duration of treatment was, on average, 7.5 days, but varied from 3 days to 2 weeks. The efficacy was assessed as "very good" or "good" in over 90 % of the cases in all age groups. No adverse effects were reported (Bässler, 2005).

4.4. Overall conclusions on clinical pharmacology and efficacy

Efficacy and tolerability of marshmallow syrup has been demonstrated in a post-marketing surveillance study in 313 children aged 3 months to 12 years and in a retrospective observational study in 599 children aged 0 to 12 years. As these studies are not randomised and controlled, their results cannot sufficiently support the well-established use for marshmallow root. They are however considered sufficient to support the traditional use as a demulcent for the symptomatic treatment of oral or pharyngeal mucosa irritation and associated dry cough. Efficacy has been demonstrated also in a double-blind, placebo-controlled clinical trial with 63 patients studying the effect of Althaea officinalis on dry cough associated with ACE inhibitors. The study cannot support the well-established use of marshmallow root as the herbal preparation was not sufficiently described. This study can nevertheless support the traditional use in dry cough.
As there are no clinical data available for indication b) (a demulcent preparation for the symptomatic relief of mild gastrointestinal discomfort) no conclusions can be drawn.

5. Clinical Safety/Pharmacovigilance

5.1. Overview of toxicological/safety data from clinical trials in humans

It the post-marketing surveillance study with 313 children by Fasse et al., 2005 an adverse event (AE) development of obstructive bronchitis and a serious adverse event (SAE), development of bronchopneumonia resulting in hospitalisation has been reported in the age group 0 to 3 years. The causal relationship of the SAE was judged by the physician as "unlikely", the causal relationship of the AE as "unrelated". The tolerability was assessed as very good to good in 97%, and satisfactory in 2.2% of patients. No other adverse effects were described.

No adverse events were reported in the retrospective observational study with 599 children (Bässler, 2005).
### Table 7: Clinical safety data from clinical trials

<table>
<thead>
<tr>
<th>Type</th>
<th>Study</th>
<th>Test Product(s)</th>
<th>Number of Subjects</th>
<th>Type of Subjects</th>
<th>Adverse reactions</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment of mucous membrane irritation in the mouth and pharynx and associated dry irritating cough</td>
<td>Post-marketing surveillance study</td>
<td>Syrup containing 35.61 g/100 g = 76.45 ml of water extract from Marshmallow root 1 : 19.5 – 23.5 2.5-10 ml 4-6 times daily Duration: 3 days in average</td>
<td>313 children (52.4 % girls, 47.6 % boys) Age groups: 0-3years n= 100; 3-6years n= 115; 6-12years n=98</td>
<td>mucous membrane irritation in the mouth and pharynx and associated dry irritating cough</td>
<td>2 cases of AE/SAE in age group 0-3 years (AE -obstructive bronchitis and SAE -bronchopneumonia)</td>
<td>the causal relationship of the SAE judged by the physician as &quot;unlikely&quot;, the causal relationship of the AE as &quot;unrelated&quot;</td>
</tr>
<tr>
<td>Efficacy and tolerability study</td>
<td>Bässler, 2005</td>
<td>Syrup containing 35.61 g/100 g = 76.45 ml of water extract from Marshmallow root 1 : 19.5 – 23.5 1-5 ml 1-6 times daily Duration: 3-14 days</td>
<td>599 children Age groups: 0-3 months n=61; 3 months -3 years n=128; 3-6years n= 188; 6-12years n=222</td>
<td>mucous membrane irritation in the mouth and pharynx and associated dry cough</td>
<td>No adverse effects reported</td>
<td>No adverse effects reported</td>
</tr>
</tbody>
</table>
5.2. **Patient exposure**

Data obtained from a post-marketing surveillance study with 313 children (Fasse et al., 2005) and from retrospective observational study with 599 children (Bässler, 2005) showed good tolerance of the water extracts of Marshmallow root.

A considerable patient/consumer exposure should be taken into consideration as marshmallow root is used as a flavouring agent in the food area.

If patients with known intolerance to *Althaea officinalis* are excluded, a traditional use is possible if administration follows the instructions as specified in the monograph.

5.3. **Adverse events, serious adverse events and deaths**

It the post-marketing surveillance study with 313 children by Fasse et al., 2005 an adverse event (AE) development of obstructive bronchitis and a serious adverse event (SAE), development of bronchopneumonia resulting in hospitalisation has been reported in the age group 0 to 3 years. No other details on the cases are available. The causal relationship of the SAE was judged by the physician as "unlikely", the causal relationship of the AE as "unrelated".

5.4. **Laboratory findings**

No data available.

5.5. **Safety in special populations and situations**

5.5.1. **Use in children and adolescents**

Efficacy and tolerability of the dry cough treatment with marshmallow root extract syrup have been demonstrated by a post-marketing surveillance study in a group of 313 children, aged from 3 months to 12.4 years (Fasse et al., 2005) and by a retrospective observational study in a group of 599 children, aged from 0-12 years (Bässler, 2005). A case of one adverse event (development of obstructive bronchitis) and a serious adverse event (development of bronchopneumonia resulting in hospitalisation) have been reported in the age group 0 to 3 years. (Fasse et al., 2005).

5.5.2. **Contraindications**

Hypersensitivity to the active substance

5.5.3. **Special Warnings and precautions for use**

**Indication 1**

If dyspnoea, fever or purulent sputum occurs during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.

**Preparations a), b) and c)**

The use in children under 3 years of age is not recommended because of concerns requiring medical advice.
Preparation d)
The use in children under 6 years of age is not recommended because of the pharmaceutical form (solid dosage form).

Preparation e)
The use in children and adolescents under 18 years of age has not been established due to lack of adequate data.

For syrup the appropriate labelling for sucrose, taken from the ‘Guideline on excipients in the label and package leaflet of medicinal products for human use’, must be included.

Indication 2)
Preparation a)
The use in children under 12 years of age has not been established due to lack of adequate data.

Preparation e)
The use in children and adolescents under 18 years of age has not been established due to lack of adequate data.

Indication 1) and 2)
Absorption of concomitantly administered medicines may be delayed. As a precautionary measure, the product should not be taken ½ to 1 hour before or after intake of other medicinal products.

If the symptoms worsen during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.

For extracts containing ethanol, the appropriate labelling for ethanol, taken from the ‘Guideline on excipients in the label and package leaflet of medicinal products for human use’, must be included.

5.5.4. Drug interactions and other forms of interaction

It is mentioned in some literature sources (Barnes et al., 2002, Hänsel et al., 1993) that absorption of concomitantly administered medicines can be delayed due to mucilage protecting layer. For this reason the product should not be taken ½ to 1 hour before or after intake of other medicinal products. As no tests on humans or animals were performed to confirm delayed absorption, this information has not been included in the section 4.5 ‘Interactions with other medicinal products and other forms of interaction’, however, it has been introduced in the section 4.4 ‘Special warnings and precautions for use’ as a precautionary measure.

5.5.5. Fertility, pregnancy and lactation

Safety during pregnancy and lactation has not been established. In the absence of sufficient data, the use during pregnancy and lactation is not recommended.

No fertility data is available.

5.5.6. Overdose

No case of overdose has been reported for marshmallow root.
5.5.7. Effects on ability to drive or operate machinery or impairment of mental ability

No studies on the effect on the ability to drive and use machines have been performed.

5.5.8. Safety in other special situations

Not applicable

5.6. Overall conclusions on clinical safety

The safety of use in defined conditions of Marshmallow root products can be derived from the long-standing use and experience as well as from clinical studies. In the post-marketing surveillance study in children one adverse event (development of obstructive bronchitis) and a serious adverse event (development of bronchopneumonia resulting in hospitalisation) has been reported in age group 0 to 3 years of age. Although the causal relationship was judged "unlikely" and/or "unrelated" it cannot be excluded. Therefore the use of Marshmallow root containing medicinal products is limited to children older than 3 years of age.

On the basis of clinical studies and information on traditional use, Marshmallow root containing medicinal products prove not to be harmful in the specified conditions of use.

The indication 1 is appropriate for use in elderly, adults, adolescents and children over 3 years of age and the indication 2 for adolescents, adults and elderly (herbal substance) or for adults and elderly (ethanolic extract) without the supervision of a medical practitioner. The duration of use without medical advice is limited to one week for indication 1 and two weeks for indication 2.

Marshmallow root preparations are contraindicated in patients with hypersensitivity to the active substance.

Due to lack of data, the use is not recommended during pregnancy and lactation.

6. Overall conclusions (benefit-risk assessment)

Based on the data documented in the assessment report, a European Union herbal monograph is established on the traditional uses of several preparations of *Althaea officinalis* L., radix. The traditional uses of Althaeae radix preparations fulfil the requirement for at least 30 years of medicinal use at a specified strength and specified posology, according to Directive 2001/83/EC as amended. None of the data fulfil the requirements to demonstrate a well-established medicinal use with recognised efficacy for Althaeae radix preparations, thus the monograph is restricted to traditional uses. The efficacy is plausible on the basis of long-standing use and experience for the following indications:

Traditional herbal medicinal product for use as a demulcent preparation

- for the symptomatic treatment of oral or pharyngeal irritation and associated dry cough
- for the symptomatic relief of mild gastrointestinal discomfort

**Benefit-Risk assessment**

The licensing of herbal medicinal products is subject to compliance with the requirements of an European Pharmacopoeia monograph. As an unambiguous macroscopic, microscopic, chemical identification of the herbal material is possible, adulteration/contamination of the herbal substance therefore is not expected.
In the clinical studies including together 912 children aged 0 – 12.4 years one adverse event (development of obstructive bronchitis) and a serious adverse event (development of bronchopneumonia resulting in hospitalisation) occurred in age group 0 to 3 years.

Although the causal relationship was judged “unlikely” and/or “unrelated” it cannot be excluded. Therefore the use of Marshmallow root containing medicinal products is limited to children older than 3 years of age.

Intoxications due to the herbal preparations are not reported in the literature/reference sources. No cases of overdose have been documented in the past 30 years.

Delayed absorption of concomitantly administered medicines is described in some literature sources, although this interaction is not confirmed by any results from tests on animals or humans. However, as a precautionary measure it is proposed to include this information in the European Union Monograph section 4.4 ‘Special warnings and precautions for use’.

There are no reports on drug abuse, effects on ability to drive or operate machinery or impairment of mental ability.

No data on laboratory findings during treatment as well as data on single- and repeat-dose toxicity, carcinogenicity, reproductive and developmental toxicity, local tolerance or other special studies of preparations from Althaeae radix, according to current state-of-the-art standards are available.

The duration of use is limited to one week for indication 1 and two weeks for indication 2 because the preparation is intended and designed for use without the supervision of a medical practitioner. Due to lack of data, the use is not recommended during pregnancy and lactation. Herbal medicinal products in liquid dosage forms containing aqueous preparations from Althaeae radix (macerates, aqueous extract) used in indication 1 are recommended for elderly, adults, adolescents and children over 3 years of age. Use in children under 3 years of age is not recommended because medical advice should be sought. Use of the products in a form of lozenges in children below six years is not advisable. The use of the herbal substance in indication 2 is recommended for adolescents, adults and elderly only. The use in children under 12 years of age is not recommended due to lack of adequate data. The use of ethanolic extract (DER 1:1, extraction solvent ethanol 25% V/V) in indications 1 and 2 is recommended for adults and elderly only. The use in children and adolescents under 18 years of age is not recommended due to lack of adequate data.

It can be concluded that the benefit-risk assessment for Althaeae radix preparations included in the monograph is positive for the use as a demulcent for the symptomatic treatment of oral or pharyngeal irritation and associated dry cough and for the symptomatic relief of mild gastrointestinal discomfort, under the specified conditions of use and at the therapeutic dosages.

The therapeutic areas for browse search on the EMA website are “Cough and cold” and “Gastrointestinal disorders”.

No constituents with known therapeutic activity or active marker can be recognised by the HMPC.

Although data on mutagenicity (AMES test) for aqueous extract from marshmallow is available, it cannot be taken into consideration as the preparation tested was not sufficiently described (no details on plant part used, and DER available). Therefore a European Union list entry cannot be supported due to lack of adequate data.

**Annex**

**List of references**